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Abstract	
	Cytochrome	 P45017A1	 (CYP17A1)	 is	 a	 multifunctional	 steroidogenic	 enzyme	responsible	 for	 the	 17a-hydroxylation	 of	 pregnenolone	 and	 progesterone	 as	well	 as	 the	subsequent	17,20	carbon-carbon	bond	scission	of	 its	hydroxylated	products	 in	a	reaction	that	constitutes	the	first	committed	step	of	androgen	formation.		Though	over	40	years	have	passed	since	discovery	of	this	enzyme,	key	questions	regarding	the	nature	of	the	reactive	intermediate	 responsible	 for	androgen	 formation	have	heretofore	 remained	unanswered.		Specifically,	 while	 the	 hydroxylase	 activity	 of	 CYP17A1	 is	 expected	 to	 proceed	 through	standard	P450	 ferryl-oxene	 intermediate,	 identity	 of	 the	 iron-oxygen	 species	 involved	 in	carbon-carbon	bond	scission	has	until	now	remained	elusive.		This	dissertation	documents	the	steady	state	kinetics	of	CYP17A1	catalysis	as	well	as	detailed	characterization	of	its	heme	environment	in	the	ferric,	oxy-ferrous,	and	peroxo-	states	by	resonance	Raman	spectroscopy	in	 order	 to	 answer	 this	 essential	 question.	 	 Presence	of	 an	 inverse	 solvent	 isotope	 effect	during	 dehydroepiandrosterone	 formation,	 as	 well	 as	 functional	 lyase	 catalysis	 by	 a	CYP17A1	mutant	 possessing	 an	 impaired	 proton-delivery	 network,	 strongly	 support	 the	hypothesis	that	a	ferric	peroxoanion	is	responsible	for	androgen	formation.	 	Additionally,	resonance	Raman	spectroscopy	of	the	oxy-ferrous	form	of	this	enzyme	revealed	that	identity	of	the	carbon-3	substituent	on	the	pregnene-	nucleus	directs	the	17a-OH	group	to	hydrogen	bond	with	the	Fe-O-O	ligand	in	a	manner	that	alternately	promotes	or	impedes	efficient	lyase	catalysis	via	 this	nucleophilic	pathway.	 	Finally,	 resonance	Raman	of	 the	during	stepwise	thermal	annealing	of	the	cryotrapped	peroxo-	state	permitted	identification	of	a	new	peroxo	
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hemiacetal	intermediate	species	initiated	by	nuclophilic	attack	on	the	substrate	molecule	by	the	peroxoanion.		As	a	whole,	this	work	details	the	structural	and	functional	properties	of	CYP17A1	active	in	human	androgen	biosynthesis.		 	
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Chapter	1:	Introduction	
	
1.1 P450	Discovery	
	 In	 1954	 Martin	 Klingenberg	 was	 a	 post-doctoral	 researcher	 at	 the	 University	 of	Pennsylvania	studying	redox	kinetics	of	cytochrome	b5,	a	12-15	kDa	hemeprotein	discovered	fifteen	years	prior.	 	While	working	with	rat	liver	homogenates,	he	discovered	a	novel	and	unknown	pigment	displaying	a	strong	absorption	band	at	450	nm	after	dithionite	reduction	and	 addition	 of	 carbon	monoxide.1	 However,	 the	 origin	 of	 this	 novel	 pigment	 remained	elusive:	attempts	at	solubilization	with	cholate	resulted	in	what	was	then	a	confounding	shift	in	absorbance	to	a	peak	at	420	nm,	and	the	absence	of	readily	apparent	a	and	b	bands	which	led	 to	 dispute	 over	 its	 hemeprotein	 nature.2	 Klingenberg	 subsequently	 abandoned	 his	investigations	 of	 this	 new	 pigment	 and	 returned	 to	 his	 home	 in	 Germany	 to	 study	mitochondrial	electron	transport,	delaying	publication	of	his	discovery	until	1958.3		 Studies	of	the	P450s	were	thus	destined	to	begin	in	earnest	some	five	years	later	in	the	laboratory	of	Ryo	Sato	at	Osaka	University.		As	an	early	career	scientist,	Sato’s	decision	to	study	this	curious	microsomal	pigment	was	largely	defined	by	friendly	conversations	he	enjoyed	 with	 Klingenberg	 and	 another	 pioneer,	 Ronald	 Estabrook	 during	 a	 visit	 to	 the	University	of	Pennsylvania	as	well	as	the	crowdedness	of	the	field	of	microsomal	electron	transport.4	He	recruited	a	young	assistant	professor,	Tsuneo	Omura	to	drive	the	work	on	this	exciting	new	project.		Omura	characterized	the	phospholipase	C	mediated	conversion	of	the	
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absorption	band	at	450	nm	to	420	nm,	and	was	able	to	perform	detailed	investigations	on	partially	solubilized	preparations	of	what	appeared	to	be	a	b-type	cytochrome.		In	1964	this	work	culminated	in	publication	of	Omura	and	Sato’s	seminal	texts	defining	the	pigment-450	nm	(P450)	and	pigment	420	nm	(P420)	as	originating	from	a	new	microsomal	hemeprotein,	which	they	named	cytochrome	P450.5		 The	intervening	60	years	have	witnessed	maturation	of	the	P450	field	and	discovery	of	 more	 than	 17,000	 members	 of	 this	 superfamily	 responsible	 for	 oxidation	 reactions	operating	on	a	rich	tapestry	of	substrates.6	The	list	of	brilliant	contributors	to	this	vast	field	is	far	too	exhaustive	to	catalog	in	this	dissertation,	however	any	author’s	discussion	of	the	history	of	P450s	would	be	 remiss	without	mention	 the	discovery	of	 the	soluble	bacterial	P450cam	by	I.C.	Gunsalus.7		The	ease	of	purification	and	stability	in	solution	exhibited	by	this	enzyme	has	 resulted	 in	 solidification	 of	 its	 role	 as	 a	mechanistic	 exemplar	 of	 the	 P450s,	providing	the	foundational	knowledge	upon	which	the	following	studies	are	based.				
1.2 Structure	and	Function	of	P450s	and	Associated	Redox	Partners	
The	ubiquity	of	the	cytochromes	P450	throughout	the	“tree	of	life”	is	a	testament	to	the	value	of	the	complex	chemistry	catalyzed	by	this	key	class	of	enzymes.		The	most	common	perception	of	P450	enzymes	is	that	of	a	vehicle	for	the	oxidation	of	unactivated	alkanes	via	a	 hydroxylase	 activity,	 however	 these	 enzymes	 are	 also	 known	 to	 catalyze	 dealkylation,	epoxidation,	 dehydrogenation,	 heteroatom	 oxidation,	 and	 carbon-carbon	 bond	 scission	reactions.8	 These	 diverse	 reactivities	 are	 employed	 in	 xenobiotic	 metabolism,	 steroid	hormone	biosynthesis	as	well	as	the	formation	of	eicosanoids	and	fatty	acids	in	humans.	
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Despite	 the	broad	range	of	 substrate	specificities	exhibited	by	members	of	 the	P450	superfamily,	these	enzymes	share	a	conserved	protein	fold	and	the	key	to	their	reactivity	is	an	 absolutely	 conserved	 protoporphyrin	 IX	 cofactor	 with	 a	 proximally	 ligated	 cysteine	residue.	 	Despite	a	conserved	fold,	there	exists	remarkable	diversity	in	detailed	structural	aspects	 and	 sequence	 identity	 among	P450s;	 as	 low	 as	 16%	 in	 some	 cases.	 	Diversity	 in	sequence	is	the	basis	for	nomenclature	identifying	specific	P450	proteins,	with	phylogenetic	criteria	and	gene	organization	being	additional	criteria.		A	CYP	prefix	identifies	the	enzyme	as	 a	 P450,	 with	 the	 following	 number	 used	 to	 identify	 a	 family	 with	 greater	 than	 40%	sequence	identity.		The	subsequent	letter	and	number	denote	a	subfamily	with	greater	than	55%	protein	sequence	identity	and	a	specific	gene,	respectively.9	There	are,	however,	several	canonical	sequences	within	the	core	of	the	P450	protein	involved	in	heme	binding	and	proton	delivery.		The	sequence	(Phe-X-X-Gly-X-Arg-X-Cys-X-Gly)	contains	the	absolutely	conserved	cysteine	residue	that	acts	as	a	fifth	ligand	to	the	heme	iron	on	 the	heme	binding	 loop.	 	Additionally,	on	 the	K-helix	a	conserved	(Glu-X-X-Arg)	 is	thought	to	be	essential	for	stabilizing	the	protein	core.10		Finally,	(A/G-G-X-Asp/Glu-T-T/S)	on	 the	 I-helix	 contains	 the	 essential	 acid/alcohol	 pair	 necessary	 for	 proton	 delivery	 to	activated	 iron-oxygen	 intermediates	 in	 the	distal	active	site	pocket.11	 	Predictably,	a	high	degree	of	sequence	variability	is	generally	observed	in	regions	involved	in	substrate	binding,	notably	in	the	B,	B’,	F,	F’	and	G	helices	which	are	thought	to	possess	conformational	flexibility	involved	in	substrate	binding.12	A	key	distinguishing	feature	between	eukaryotic	and	prokaryotic	P450s	is	the	presence	of	an	N-terminal	membrane	anchor	on	the	latter.		Unlike	soluble	prokaryotic	P450s,	those	in	eukaryotes	 are	 typically	 bound	 to	 the	 membrane	 of	 the	 endoplasmic	 reticulum	 or	
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mitochondrial	inner	membrane	via	a	hydrophobic	20-50	amino	helix.		In	P450s	associated	to	 the	 mitochondrial	 membrane,	 this	 membrane	 anchor	 is	 expressed	 with	 a	 targeting	sequence	 that	 is	 subsequently	 cleaved	 during	 import	 into	 the	 mitochondrion,	 whereas	microsomal	 P450s	 are	 inserted	 co-translationally	 without	 processing.13	 Membrane	association	is	also	enhanced	in	these	proteins	via	a	longer	peptide	chain	spanning	the	region	between	the	F	and	G	helices	that	form	a	hydrophobic	patch	thought	to	be	in	close	proximity	to,	or	buried	in	the	membrane.14,15				Despite	 catalytic	 activity	 observed	 in	 some	 membrane	 associated	 P450s	 following	solubilization	 via	 truncation	 of	 their	 hydrophobic	 tail,	 proper	 in	 vivo	 function	 is	 highly	dependent	on	their	insertion	into	the	membrane.		A	large	number	of	substrates	are	highly	hydrophobic	and	partition	preferentially	into	lipid	bilayers.		Juxtaposition	of	the	active	site	near	 the	membrane	 is	 expected	 to	 facilitate	 delivery	 of	 hydrophobic	 substrates	 to	 P450	systems	 operating	 on	 such	 molecules,	 such	 as	 in	 the	 CYP11A1	 mediated	 cleavage	 of	isocaproic	 acid	 from	 cholesterol.16	 Additionally,	 N-terminal	 membrane	 anchoring	 is	 an	essential	orienting	factor	in	generation	of	functional	electron	transfer	complexes	involving	P450s	 and	 their	 various	 redox	 partners	 in	 the	 protein	milieu	 of	 the	 bilayer17	 and	 close	association	to	the	membrane	is	thought	to	be	an	important	modulator	of	redox	potential	in	these	complexes.18,19		P450	 mediated	 oxidation	 is	 dependent	 on	 not	 only	 the	 presence	 of	 substrate	 and	enzyme,	but	also	input	of	atmospheric	dioxygen	and	reducing	equivalents,	the	delivery	of	which	is	generally	mediated	by	accessory	proteins.		In	the	case	of	human	microsomal	P450s,	cytochrome	 P450	 oxidoreductase	 (CPR)	 orchestrates	 sequential	 delivery	 of	 electrons	derived	 from	 NADPH	 to	 the	 heme	 cofactor.20	 CPR	 is	 a	 multidomain	 78,000	 Da	 protein	
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containing	 flavin	adenine	dinucleotide	 (FAD)	and	 flavin	mononucleotide	 (FMN)	 cofactors	anchored	to	the	membrane	via	a	hydrophobic	tail	that	facilitates	efficient	orientation	with	the	P450	in	conjunction	with	additional	electrostatic	interactions.		In	this	system,	the	FAD	cofactor	accepts	two	reducing	equivalents	from	NADPH	and	sequentially	transfers	these	to	the	FMN	domain,	which	act	as	an	adapter	between	the	two-electron	transfer	from	NADPH	and	the	requisite	one-electron	reduction	needed	for	proper	P450	function.21,22		In	mitochondrial	P450	systems,	another	redox	shuttle	is	operating,	composed	of	a	three-protein	system	constituting	a	P450,	 ferredoxin	reductase	and	ferredoxin	adrenoxodin.	 	 In	such	 systems	 a	 FAD	 cofactor	 in	 ferredoxin	 reductase	 accepts	 electrons	 from	NADPH	and	subsequently	reduces	the	2Fe-2S	cluster	of	adrenoxodin	that	acts	as	a	one-electron	shuttle	to	the	P450.23		
1.3	The	P450	Reaction	Cycle	
	 After	nearly	60	years	of	intensive	study,	a	general	consensus	has	emerged	regarding	the	 nature	 of	 reactive	 intermediates	 involved	 in	 P450	 function	 (Figure	 1.1).	 	Worthy	 of	mention	 at	 this	 juncture	 is	 the	 depth	 in	which	 this	 field	 has	 been	 studied,	 therefore	 this	section	 is	 intended	 as	 merely	 an	 overview	 of	 the	 mechanics	 of	 P450	 mediated	 oxygen	activation—more	 substantive	 discussion	 of	 the	 intricacies	 of	 the	 complex	 chemistries	operating	in	this	cycle	will	follow	in	later	chapters.				 In	the	resting	P450	state	[1]	the	ferric	heme	iron	possesses	a	molecule	of	water	as	a	sixth	ligand	and	is	the	(S=1/2)	low	spin	state.		Substrate	binding	generally	displaces	water	as	a	ligand	resulting	in	a	rearrangement	of	d-orbital	electrons,	shifting	the	equilibrium	to	the	
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S=5/2	 high	 spin	 state	 [2]	 with	 a	 concomitant	 ~100mV	 increase	 in	 redox	 potential.24	Increased	 redox	 potential	 enhances	 electron	 transfer	 from	 an	 associated	 redox	 partner,	which	once	delivered	results	in	formation	of	ferrous	heme	[3]	that	readily	binds	a	molecule	of	dioxygen	forming	the	oxy-ferrous	complex	[4].25		This	adduct	represents	the	first	unstable	intermediate	 and	 may	 either	 decompose	 via	 the	 autoxidation	 route	 with	 release	 of	superoxide	and	a	return	to	the	ferric	state,	or	proceed	productively	via	a	second	one-electron	reduction	and	formation	of	the	peroxoanion	species.				 	Delivery	of	a	single	proton	 to	 the	distal	oxygen	of	 the	peroxoanion	 [5a]	results	 in	formation	of	 the	hydroperoxoanion	[5b],	another	uncoupling	point	at	which	the	peroxide	ligand	may	be	non-productively	released	as	a	hydrogen	peroxide.	 	Alternatively,	a	second	protonation	of	the	distal	oxygen	and	subsequent	heterolytic	O-O	bond	scission	may	release	a	molecule	of	water	and	form	the	high-valent	iron-oxo	Compound	I	(CpdI)	[6]	with	a	cation	radical	delocalized	on	the	porphyrin.26		This	adduct	has	been	the	focus	of	considerable	study	and	 is	 generally	 regarded	 as	 the	 active	 intermediate	 responsible	 for	 the	 overwhelming	majority	of	P450	mediated	reactions.		In	the	“Groves	Rebound”	mechanism,	CpdI	abstracts	a	hydrogen	atom	 from	 the	 substrate,	 forming	an	 iron	 (IV)	hydroxide	 transient	 that	 rapidly	recombines	 to	 the	 substrate	 radical	 to	 yield	 the	 final	 hydroxylated	 product	 and	 ferric	iron.27,28			As	with	other	unstable	intermediates,	though,	CpdI	abortive	reactions	involving	this	adduct	are	possible	via	further	2-electron	reduction	and	release	of	a	water	molecule.		 	
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1.4	Human	Steroid	Hormone	Biosynthesis	
Steroid	hormone	biosynthesis	is	a	tightly	regulated	process	essential	for	development	and	maintenance	of	the	normal	human	phenotype.		Primarily	occurring	in	the	adrenal	and	gonadal	 tissues,	 the	 steroid	 precursor	 cholesterol	 is	 subjected	 to	 a	 bevy	 of	 chemical	transformations	 responsible	 for	 the	 formation	 of	 mineralocorticoids,	 glucocorticoids,	androgens,	and	estrogens.		Production	and	systemic	delivery	of	these	steroid	molecules	is	essential	in	maintenance	of	salt	and	water	balance,	carbohydrate	metabolism,	catecholamine	response,	and	sexual	development.29	The	overall	process,	shown	in	Figure	1.2,	is	dependent	upon	 the	 actions	 of	 six	 cytochrome	 P450	 enzymes	 and	 several	 steroid	 dehydrogenases	distributed	throughout	the	mitochondrial	inner	membrane	and	endoplasmic	reticulum.30			 		All	steroids	are	derived	from	cholesterol,	primarily	originating	from	dietary	sources,	and	delivered	to	steroidogenic	tissues	incorporated	in	high-density	lipoprotein	particles.31	Cellular	 cholesterol	 uptake	 is	 primarily	mediated	by	 endocytosis	 of	 lipoprotein	particles,	followed	by	transport	to	the	outer	mitochondrial	membrane.		In	the	subsequent	step	that	is	rate	 limiting	 for	 overall	 steroid	 synthesis,	 cholesterol	 is	 transported	 into	 the	 inner	mitochondrial	membrane	by	steroidogenic	acute	regulatory	protein	(StAR)32,	a	37,000	Da	phosphoprotein.		In	the	first	enzymatic	step	of	steroid	hormone	biosynthesis,	cholesterol	is	subjected	to	three	processive	reactions	by	a	single	enzyme,	CYP11A1,	ultimately	resulting	in	formation	of	pregnenolone	and	release	of	isocaproaldehyde.33		 The	multiple	reactivities	of	Cytochrome	P45017A1	(CYP17A1)	lie	here,	at	the	heart	of	 this	pathway,	and	define	a	key	branch	point	at	which	steroid	hormone	precursors	are	directed	 towards	 corticoid	 production	 or	 committed	 to	 formation	 of	 androgens	 and	estrogens.34	Pregnenolone	(PREG)	may	be	subjected	to	hydroxylation	by	CYP17A1	to	form	
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17a-hydroxyprenenolone	 (17-OH	 PREG)	 or	 conversion	 of	 the	 alcohol	 on	 carbon-3	 and	isomerization	of	the	B-ring	double	bond	to	form	progesterone	(PROG)	in	a	reversible	process	dependent	on	the	activity	of	3b-hydroxysteroid	dehydrogenase	and	NAD+	input.35		CYP17A1	 catalyzes	 an	 analogous	 hydroxylation	 on	 carbon-17	 of	 progesterone,	forming	 the	 17a-hydroxyprogesterone	 product	 (17-OH	 PROG).	 	 It	 is	 at	 this	 key	 point	 at	which	the	CYP17A1	products	may	be	subjected	to	a	round	of	17,20	carbon-carbon	scission	forming	 the	19	 carbon	androgens	dehydroepiandrosterone	 (DHEA)	and	androstenedione	(AD).			Alternatively,	both	progesterone	and	hydroxyprogesterone	may	be	further	processed	by	P450c21	which	introduces	an	alcohol	functionality	to	carbon-21,	directing	these	products	towards	 formation	 of	 mineralcorticoids	 and	 glucocorticoids,	 respectively.36	 The	deoxycorticosterone	 and	 11-deoxycortisol	 products	 of	 the	 former	 process	 are	 further	processed,	 once	 more,	 in	 the	 mitochondria	 by	 CYP11B2	 in	 a	 straightforward	 11b-hydroxylase	 reaction	 forming	 corticosterone	 and	 cortisol.37	 An	 isozyme	 sharing	 a	 93%	sequence	identity,	CYP11B1,	is	expressed	only	in	tissues	producing	aldosterone	and	is	able	to	catalyze	the	sequential	C-18	hydroxylation	of	deoxycoricosterone	as	well	as	the	18-methyl	oxidase	activity	responsible	for	formation	of	aldosterone.38	Focusing	on	the	steroid	production	directed	towards	androgen	formation,	both	AD	and	DHEA	are	subjected	to	additional	downstream	processing	as	they	are	directed	toward	the	 production	 of	 testosterone,	 dihidrotestosterone	 and	 the	 18	 carbon	 estrogens.	 	 The	complexity	of	this	latter	pathway	precludes	a	detailed	description	in	this	text,	as	there	are	multiple	isoforms	of	the	various	enzymes	and	“backdoor”	pathways	operating.29		However,	the	process	can	be	reduced	to	the	statement	that	flux	through	this	pathway	in	humans	occurs	
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via	 DHEA	 isomerization	 via	 the	 action	 of	 3b-HSD	 forming	 AD,	 which	 is	 either	 directed	towards	 estrogen	 production	 by	 CYP19	 mediated	 A-ring	 aromatization	 and	 10,19	 C-C	cleavage	 or	 towards	 testosterone	 production	 via	 reduction	 of	 the	 C-20	 keto	 group	 to	 an	alcohol	by	17b-hydroxysteroid	dehydrogenase.39				 	
1.5	CYP17A1	
As	described	above	and	shown	 in	Figure	1.2,	 the	multifunctional	human	CYP17A1	plays	 a	 central	 role	 in	 the	 steroidogenic	 pathway,	 catalyzing	 the	 17α-hydroxylation	 of	pregnenolone	and	progesterone	as	well	as	the	subsequent	17,20	carbon-carbon	lyase	of	its	hydroxylated	 products	 to	 form	 dehydroepiandrosterone	 and	 androstenedione.36,40	 	 The	various	activities	of	CYP17A1	represent	crucial	branch	points	in	human	steroidogenesis	and	are	absolutely	essential	for	both	glucocorticoid	and	androgen	production.		Consistent	with	its	functional	significance,	polymorphisms	affecting	the	activity	of	CYP17A1	are	deleterious	to	 normal	 human	 physiology.	 	 Congenital	 adrenal	 hyperplasia	 secondary	 to	 CYP17A1	deficiency	has	been	known	to	manifest	as	symptoms	of	hypertension	and	abnormal	sexual	development	in	afflicted	individuals.		Additionally,	owing	to	its	key	role	in	the	generation	of	sex	hormones	this	enzyme	has	become	a	front-line	target	for	inhibition	in	the	treatment	of	androgen	receptor	positive	prostate	cancer,	reinvigorating	the	half-century	old	practice	of	androgen	deprivation	therapy	for	the	treatment	of	this	malady.41,42			Human	CYP17A1	 is	 a	~57,000	Da	protein	 localized	 in	 the	 endoplasmic	 reticulum	membrane	of	tissues	of	the	adrenals,	testes,	and	ovaries.		As	a	microsomal	P450,	CYP17A1	activity	is	dependent	on	cytochrome	P450	oxidoreductase	(CPR)	for	electron	input,	but	has	
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an	 additional	 requirement	 of	 the	presence	of	 cytochrome	b5	 (cyt	 b5)	 to	 catalyze	 carbon-carbon	bond	scission.43–45	Maximal	velocity	of	this	latter	chemistry	is	enhanced	up	to	10-fold	in	 the	 presence	 of	 cyt	 b5,	 whereas	 the	 hydroxylase	 activity	 is	 largely	 unaffected	 by	 the	presence	of	this	effector.17		Additional	studies	suggest	that	phosphorylation	at	several	key	positions	 can	 similarly	 enhance	 C-C	 bond	 scission.46–48	 	 Both	 expression	 of	 cyt	 b5	 and	activation	 of	 CYP17A1	 phosphorylation	 in	 the	 adrenal	 Zona	 reticularis	 coincides	 with	andrenarche	 and	 initiation	 of	 androgen	 production	 in	 adrenal	 tissues,	 suggesting	 these	processes	 are	 key	 regulatory	 elements	 in	 controlling	 sex	 hormone	 production.49	 	 This	represents	an	important	method	of	temporal	control	over	sex	hormone	production,	delaying	this	process	until	andrenarche	while	maintaining	17a-hydroxylase	activity	which	is	required	throughout	the	entire	lifespan	of	an	individual.				 	A	 central	 question	 regarding	 CYP17A1	mediated	 catalysis	 has	 long	 remained	 the	nature	 of	 the	 reactive	 intermediate	 responsible	 for	 cleavage	 of	 the	 17,20	 carbon-carbon	bond	on	the	steroid,	resulting	in	the	release	of	acetic	acid	and	androgen	product.		Whereas	it	is	 clear	 that	 the	 hydroxylase	 activity	 of	 CYP17A1	 proceeds	 via	 a	 straightforward	 CpdI	mediated	“Groves	rebound”	mechanism,	a	role	for	a	nucelophilic	peroxoanion	in	initiation	of	C-C	scission	in	the	formation	of	androgens	has	been	suggested.50–53	In	such	an	event,	attack	of	the	electrophilic	center	of	the	C-20	carbonyl	by	a	peroxoanion	would	result	in	formation	of	an	peroxo	hemiacetal	intermediate	that	could	then	decompose	via	either	heterolytic	or	homolytic	 scission	 of	 the	 dioxygen	 bond	 to	 yield	 androgen	 product	 and	 acetic	 acid.		Alternatively,	radical	mechanisms	utilizing	CpdI	as	the	active	oxidant	have	been	proposed	that	could	decompose	to	the	androgen	product	as	shown	in	in	Figure	1.3.34,54			 	
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1.6:	Tables	and	Figures	
															
Figure	1.1:	The	P450	Catalytic	Cycle	The	canonical	P450	catalytic	cycle.		 	
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Figure	1.2:	Human	Steroid	Biosynthetic	Pathway	The	human	steroid	hormone	biosynthetic	pathway,	beginning	with	cholesterol,	and	ending	with	corticoids,	androgens,	and	estrogens.		The	inset	on	the	lower	right	indicates	numbering	of	the	carbon	atoms	on	the	cholesterol	molecule.		 	
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Figure	1.3:	Proposed	Mechanisms	of	Androgen	Biosynthesis	Proposed	 mechanisms	 involving	 a	 reactive	 peroxo	 intermediate	 (A)	 beginning	 with	 a	nucleophilic	 attack	 on	 the	 C20	 carbonyl	 and	 CpdI	 (B),	 initiated	 by	 abstraction	 of	 the	hydrogen	atom	on	the	17-OH	group.			 	
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Chapter	2:	Methods	for	Reconstitution	of	CYP17A1	
in	Nanodiscs	with	Associated	Redox	Partners	
	
2.1	Introduction	
Groundbreaking	work	by	 the	Waterman	 laboratory	 in	 the	 late	1980’s	 identified	5’	sequence	 modifications	 to	 native	 bovine	 and	 human	 CYP17A1	 cDNA	 permitting	heterologous	expression	of	milligram	quantities	of	this	enzyme	in	E.	coli,	making	this	the	first	mammalian	 P450	 to	 be	 expressed	 in	 high	 yield.55–57	 	 However,	 despite	 development	 of	expression	systems	 in	E.	 coli,	 Yeast,	 and	SF9	cells,	 the	detergent	 solubilized	preparations	yielded	 by	 these	 early	methods	 represent	 a	 suboptimal	 platform	 for	 characterization	 by	many	commonly	used	in	vitro	methods	in	the	biochemist’s	toolbox.		Though	such	treatment	was	demonstrated	 to	provide	soluble	and	highly	purified	protein,	 these	 targets	exist	 in	a	decidedly	 non-native	 environment	 hampering	 the	 efforts	 of	 investigators.	 	 Oligeromeric	states	 are	 difficult	 to	 control,	 substrate	 molecules	 may	 partition	 preferentially	 into	 the	detergent	micelles,	and	in	the	absence	of	stabilizing	protein-membrane	interactions	targets	of	 interest	may	adopt	non-native	 functional	properties	or	 fail	 to	 form	 functional	protein-protein	interactions	in	which	membrane	association	is	an	important	orienting	factor.58,59					These	impediments	are	overcome	via	incorporation	of	target	proteins	into	Nanodiscs.		These	 nanoscale	 particles	 are	 monodisperse,	 discoidal	 lipid	 bilayers	 solubilized	 by	 an	encircling	 amphipathic	 scaffold	protein.	 	These	nanoscale	particles	 are	 formed	 through	a	self-assembly	 process	 in	which	 detergent	 is	 removed	 from	 a	 solution	 containing	 precise	
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ratios	of	target	membrane	protein,	lipid,	and	scaffold	protein.60,61		The	end	product	of	this	process	is	a	stable	and	soluble	platform	that	renders	membrane	proteins	amenable	to	the	rigorous	interrogation	previously	reserved	for	soluble	proteins.				
2.2	Expression	and	Purification	of	CYP17A1	
2.2.1	Design	of	a	synthetic	human	CYP17A1	gene	A	 full	 length	 gene	 was	 designed	 including	 a	 C-terminal	 penta-histidine	 tag	 for	purification	 based	 on	 the	 CYP17A1	 cDNA	 sequence	 available	 from	 GenBank,	 accession	number	NM_000102,	version	NM_000102.3.		The	first	twenty-four	5’	bases	were	modified	as	reported	by	Imai	et	al.57	to	improve	heterologous	expression	and	include	an	NdeI	restriction	endonuclease	site	in	the	start	codon,	resulting	in	a	total	of	five	amino	acid	substitutions	in	the	hydrophobic	tail	of	CYP17A1,	such	that	5’-	GAG	GTA	AAA	CAT	ATG	GCT	CTG	TTA	TTA	GCA	 GTT	 TTC	 –	 3’.	 	 The	 remaining	 codons	 were	 optimized	 for	 E.	 coli	 expression	 by	 a	proprietary	 process	 of	 DNA	 2.0,	 and	 an	 XbaI	 restriction	 site	 was	 added	 immediately	following	the	stop	codon.		A	full	sequence	is	included	in	Appendix	A.		The	resultant	gene	was	ligated	into	a	pCWori+	plasmid	conferring	ampicillin	resistance.		Competent	DH5α	F’IQ	cells	(Invitrogen)	were	co-transformed	with	the	ligation	product	and	the	pGro7	vector	(Takara	Bio),	containing	GroEL/ES	and	conferring	chloramphenicol	resistance.		Glycerol	stocks	were	prepared	from	50	mL	cultures	of	transformed	cells	and	were	stored	at	-80°C	for	future	use.	
2.2.2	Expression	of	P45017A1	Each	 expression	 session	 was	 initiated	 by	 the	 plating	 of	 DH5α	 containing	pCW_CYP17A1	 and	pGro7	 vectors	 from	glycerol	 stock	 onto	 LB-agar	 plates	 containing	 20	
	 16	
µg/mL	chloramphenicol	and	100	µg/mL	ampicillin.		Plates	incubated	overnight	at	37°C	and	a	single	isolated	colony	was	selected	to	inoculate	50	mL	LB	containing	20	µg/mL	and	100	
µg/mL	 ampicillin.	 	 This	 starter	 culture	 generally	 incubated	 at	 37°C	 for	 6-8	 hours	 while	rotating	at	250	RPM.		1	mL	of	starter	culture	was	used	to	inoculate	each	1	L	volume	of	Terrific	Broth	 containing	 1X	 Bracken’s	 Trace	Metals	 Solution,	 33.7	mg/mL	 thiamine,	 100	µg/mL	ampicillin	 and	 20	µg/mL	 chloramphenicol	 contained	 in	 a	 2.8L	 Fernbach	 flask.	 	 Cultures	incubated	 at	 37°C	 while	 rotating	 at	 250	 RPM	 until	 OD600	 reached	 0.4-0.6.	 	 At	 this	 time	cultures	were	 transferred	 to	 a	 27°C	 incubator	 programmed	 to	 rotate	 at	 220RPM	 and	 δ-aminolevulinic	acid	was	added	to	a	final	concentration	of	1	mM.		When	OD600	reached	0.8,	expression	 of	 CYP17A1	 and	 GroEL/ES	 was	 induced	 by	 the	 addition	 of	 isopropyl	 b-D-1-thiogalactopyranoside	 and	powdered	 L-Arabinose	 to	 final	 concentrations	 of	 1	mM	and	4	mg/mL,	respectively.		Cultures	incubated	at	27°C	while	rotating	at	250	RPM	for	40-48	hours,	at	which	point	cells	were	pelleted	by	centrifugation	at	11,000	x	g	for	10	minutes.		Cell	pellets	were	stored	at	-80°C	until	purification.	
2.2.3	Purification	of	P45017A1	Frozen	cell	pellets,	typically	25-30	g/L,	from	6	L	culture	were	resuspended	in	270mL	lysis	buffer	(0.1M	KPi	pH	7.4,	0.05	M	NaCl,	20%	glycerol,	50	µM	Progesterone,	10	mM	B-Me,	0.5	mM	PMSF,	0.1mg/mL	lysozyme,	0.1	mg/mL	DNase,	0.1	mg/mL	RNase).		Lysis	solution	stirred	 at	 4°C	 for	 45	minutes.	 	 Resultant	 spheroplasts	 were	 lysed	 by	 sonication	 using	 a	Branson	Sonifier	450	attached	to	a	0.5	cm	probe.		Lysis	solutions	were	subjected	to	six,	two	minute	cycles	at	0.6	output	and	70%	duty	cycle	with	five	minute	incubations	on	ice	between	cycles.			
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The	lysate	was	subsequently	centrifuged	at	100,000	x	g	for	30	minutes	at	4°C	and	the	supernatant	 was	 discarded	 and	 membrane	 pellets	 resuspended	 in	 270	 mL	 membrane	solubilization	buffer	(0.1M	KPi	pH	7.4,	0.5	M	NaCl,	20%	glycerol,	50	µM	Progesterone,	10	mM	B-Me,	 0.5	mM	 PMSF)	 by	 stirring	 for	 1	 hour	 at	 4°C.	 	 To	 solubilize	membrane	 associated	proteins,	 20%	 Triton	 X-100	was	 added	 dropwise	 until	 the	 final	 detergent	 concentration	reached	 1.5%.	 	 This	 solution	 incubated	 at	 4°C	 while	 stirring	 for	 1	 hour,	 and	 was	 then	centrifuged	 at	 100,000	 x	 g	 for	 30	 minutes	 at	 4°C.	 	 Supernatant	 containing	 solubilized	membrane	proteins	was	collected	and	the	insoluble	membrane	fraction	discarded.			The	solubilized	 fraction	was	 immediately	purified	by	Ni2+	affinity	chromatography	utilizing	a	2.5x12cm	column	containing	a	20	mL	bed	of	nitrilotriacetic	acid	agarose	resin	(Qiagen)		attached	to	a	peristaltic	pump	and	fraction	collector	at	a	flow	rate	of	approximately	3.0	mL/min.		The	column	was	charged	with	0.1M	NiSO4,	washed	extensively	with	water,	and	equilibrated	with	 4	 column	 volumes	 of	membrane	 solubilization	 buffer	 containing	 1.5%	Triton	X-100.		The	entire	volume	of	solubilized	membrane	fraction	was	then	loaded	onto	the	column.		The	column	was	washed	first	with	5	column	volumes	of	Wash	Buffer	A	(0.05	M	Tris,	pH	7.4,	0.3	M	NaCl,	20%	Glycerol,	50	µM	Progesterone,	0.02%	Emulgen	913,	10	mM	B-Me),	and	then	10	column	volumes	of	Wash	Buffer	B	(Wash	Buffer	A	with	50mM	Imidazole,	5	mM	adenosine	 triphosphate,	 and	 20	 mM	 MgCl2.	 	 Bound	 protein	 was	 eluted	 with	 2	 column	volumes	of	Elution	Buffer	(0.05	M	Tris	pH	7.4,	0.05	M	NaCl,	20%	Glycerol,	0.02%	Emulgen	913,	50	µM	progesterone,	10	mM	b-Me,	300	mM	imidazole)	and	collected	in	4mL	fractions.			Colored	fractions	were	pooled	and	dialyzed	once	overnight	against	1	L	of	0.1M	KPi	pH	7.4,	20%	Glycerol,	0.05	M	NaCl,	50	µM	Progesterone,	10	mM	B-Me,	2	mM	EDTA	at	4°C	in	a	 10,000	 MWCO	 membrane,	 and	 twice	 against	 the	 same	 buffer	 without	 EDTA.	 	 Finally,	
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protein	was	and	concentrated	to	~100	μM	in	a	15mL	centrifugal	concentrator	with	a	10,000	MWCO	(Millipore),	 flash	frozen	in	 liquid	N2	and	stored	at	-80°C.	 	P450	concentration	was	determined	by	the	method	of	Omura	and	Sato.		
2.3	CYP17A1	Nanodisc	Self-Assembly	
Generally,	 32	 μmol	 POPC	 in	 choloform	 was	 delivered	 to	 borosilicate	 tubes	 in	triplicate,	dried	under	a	stream	of	nitrogen,	and	dessicated	under	vacuum	overnight.		Dried	POPC	was	hydrated	 in	a	1.73	mL	solution	of	0.1M	KPi	pH	7.4	and	0.05M	NaCl	with	 three	sequential	steps	of	vortexing,	freezing	in	liquid	N2,	and	thawing	at	room	temperature.		Triton	X-100	was	added	in	a	1.15:1	molar	ratio	to	lipid	and	solution	was	sonicated	for	30	minutes	at	60°C	in	order	to	assist	complete	solubilization	of	the	dried	lipid.		The	final	reconstitution	solution	contained	10mM	POPC,	0.3M	NaCl,	0.1M	KPi	pH	7.4,	40mM	Triton	X-100,	154μM	MSP1D1-,	7.7μM	P45017A1,	50μM	progesterone,	and	10mM	B-Me.		This	mixture	incubated	on	ice	for	30	minutes,	at	which	point	8	grams	of	wet	Amberlite	XAD-2	(Supelco)	was	added,	and	the	solution	was	incubated	at	4°C	on	a	shaker	for	6	hours.		Amberlite	was	removed	and	washed	with	buffer	C	(0.1	M	KPi,	pH	7.4,	300mM	NaCl),	and	the	resultant	solution	was	pooled	with	the	extracted	reconstitution	mixture	and	loaded	onto	a	7	mL	Ni-NTA	column	to	separate	empty	Nanodiscs	 from	 those	with	 embedded	CYP17A1.	 	 The	 column	was	washed	with	5	volumes	of	buffer	C	containing	30	mM	imidazole,	and	eluted	with	buffer	C	supplemented	with	300	mM	imidazole.		The	eluate	was	loaded	onto	a	Superdex	200	10/300GL	column	(GE	Life	Sciences)	using	a	0.1	M	KPi,	pH	7.4,	mobile	phase	at	a	flow	rate	of	0.5	mL/min.		10	nm	fractions	corresponding	to	properly	formed	Nanodiscs	were	pooled	and	concentrated,	and	
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stored	in	15%	(v/v)	glycerol	at	-80°C	until	required.		The	concentration	of	Nanodiscs	was	determined	by	the	difference	spectrum	of	substrate	free	and	pregnenolone	bound	protein	using	the	peak	to	trough	extinction	coefficient	of	e390	-	e420	=	100	mM-1	cm-1.62	
2.4	Expression	and	Purification	of	Redox	Partners	and	Cyt	b5	
2.4.1	Expression	of	Cytochrome	P450	Oxidoreductase	Cytochrome	P450	oxidoreductase	was	expressed	and	purified	by	a	modified	method	of	Shen	et.	al.63	 	CD41	cells	transformed	with	plasmid	pOR262	containing	full-length	wild	type	rat	 liver	CPR	was	a	generous	gift	 from	Todd	Porter.63	 	Each	growth	was	 initiated	by	streaking,	 from	glycerol	 stock,	 an	agar	plate	 containing	100	µg/mL	ampicillin	which	was	subsequently	grown	overnight	at	37°C.	 	 Starter	 culture	was	grown	 in	50	mL	 flasks	of	LB	media	 containing	 100	 µg/mL	 ampicillin	 while	 shaking	 at	 220	 RPM	 at	 37°C	 until	 OD600	reached	0.4.		CPR	was	typically	expressed	in	12	L	batches,	consisting	of	12	x	2.8	L	Fernbach	flasks	containing	Luria-Bertan	Media	supplemented	with	100	µg/mL	ampicillin	and	1	µg/mL	riboflavin,	 inoculated	with	8	mL	of	starter	culture.	 	Flasks	were	maintained	at	33°C	while	shaking	at	220	RPM,	and	were	induced	with	1	mM	IPTG	at	OD600	=	1.0.		After	~20	hours	of	growth	cells	were	harvested	by	centrifugation	at	11,000	x	g	for	10	minutes	and	stored	at	-80°C	until	purification.	
2.4.2	Purification	of	Cytochrome	P450	Oxidoreductase		 Cells	from	6	L	culture	were	thawed	and	resuspended	in	2.4	L	lysozyme	buffer	(0.75	M	Tris	pH	8.0,	0.25	M	sucrose,	250	µM	EDTA,	0.02	mg/mL	lysozyme)	while	stirring	at	4°C	for	2	hours,	and	the	resultant	spheroplasts	harvested	by	centrifugation	at	11,000	x	g	for	30	
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minutes.		Cells	were	then	resuspended	in	lysis	buffer	(0.05	M	Tris	pH	8.0,	1	mM	PMSF)	and	lysed	on	ice	by	sonication	using	a	Branson	Sonifier	with	a	0.5	cm	probe	and	80%	duty	cycle,	with	the	output	set	to	4	using	5	x	30	second	pulses.		The	membrane	fraction	was	then	isolated	by	centrifugation	at	100,000	x	g	for	30	minutes.				 After	complete	resuspension	of	membrane	pellet	in	260	mL	MQ	H2O,	the	remaining	solubilization	buffer	 components	were	 added	 such	 that	 the	 concentrations	of	 each	were:	0.05	M	Tris	pH	7.7,	0.1	mM	EDTA,	0.1	mM	DTT,	20	%	v/v	glycerol,	0.5	M	NaCl,	0.2%	Triton	X-100.		The	resultant	suspension	stirred	at	4°C	for	2	hours	and	the	insoluble	fraction	was	pelleted	 at	 185,000	 x	 g	 for	 1	 hour.	 	 The	 supernatant	was	 loaded	on	 a	 25	mL	bed	of	 2’5’	adenosine	diphosphate	agarose	column	equilibrated	with	ADP	column	buffer	(0.05	M	Tris	pH	7.7,	0.1	mM	EDTA,	0.1	mM	DTT,	20	%	v/v	glycerol,	0.1%	Triton	X-100).		The	column	was	then	washed	with	200	mL	ADP	wash	buffer	(ADP	column	buffer	supplemented	with	2	mM	adenosine).	 	 Bound	 protein	 was	 eluted	 with	 ADP	 elution	 buffer	 (ADP	 column	 buffer	containing	2	mM	NADPH).		Detergent	was	removed	by	immobilization	on	a	1.5	x	10	cm	DE-52	DEAE	column	equilibrated	and	washed	with	DEAE	column	buffer	(0.05	M	Tris	pH	7.7,	0.1	mM	EDTA,	0.1	mM	DTT,	20	%	v/v	glycerol)	until	absorbance	of	the	eluting	buffer	was	less	than	0.1	at	280	nm.		Purified	CPR	was	eluted	with	DEAE	column	buffer	containing	0.4	M	NaCl,	and	 was	 dialyzed	 against	 3	 L	 DEAE	 column	 buffer	 with	 three	 buffer	 exchanges.		Concentration	 of	 purified	 CPR	 was	 determined	 spectrophotometrically	 after	 complete	oxidation	with	potassium	ferricyanide	using	e455	=	21.4	mM-1	cm-1.	
2.4.3	Expression	of	Cytochrome	b5	Cytochrome	 b5	 from	 Rattus	 norvegicus	 was	 expressed	 and	 purified	 in	 a	 modified	method	 as	 described	by	 the	Waskel	 laboratory64	 using	 a	 pET15b	plasmid	 containing	 full	
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length	 cyt	 b5	with	 an	N-terminal	membrane	 anchor.	 	 Transformed	BL-21gold(DE3)	 cells	were	plated	from	glycerol	stock	on	agar	plates	containing	100	µg/mL	ampicillin	and	grown	overnight	at	37°C.		Starting	culture	was	then	prepared	by	delivery	of	a	single	colony	to	a	50	mL	volume	of	LB	media	containg	100	µg/mL	ampicillin	which	rotated	at	220	RPM	at	37°C	for	8	hours.		Fernbach	flasks	containing	500	mL	terrific	broth	supplemented	with	100	µg/mL	ampicillin	and	1X	Bracken’s	Trace	Metal	Solution	were	inoculated	with	5	mL	starting	culture	and	incubated	at	37°C	while	rotating	at	200	RPM.		At	OD600	=	0.8,	d-ALA	and	IPTG	were	added	to	a	final	concentration	of	0.5	mM	and	1	mM,	respectively.		Cultures	continued	to	incubate	for	20	hours	and	cells	were	then	harvested	via	centrifugation	at	11,000	x	g	for	15	minutes	and	stored	at	-80°C	until	purification.	
2.4.4	Purification	of	Cytochrome	b5	 	Purification	 began	 with	 resuspension	 of	 cell	 pellet	 from	 12	 L	 of	 culture	 in	 2.4	 L	lysozyme	buffer	(0.075	M	Tris	pH	8.0,	0.25	M	sucrose,	0.25	mM	EDTA,	0.02	mg/mL	lysozyme)	for	 30	minutes	 while	 stirring	 at	 4°C.	 	 Spheroplasts	 were	 harvested	 by	 centrifugation	 at	11,000	x	g	for	30	minutes	and	the	pellet	was	then	resuspended	in	lysis	buffer	360	mL	lysis	buffer	(20	mM	KPi	pH	7.0,	1	mM	EDTA,	2.5	mM	PMSF)	and	lysed	via	five	rounds	of	sonication	on	ice	with	a	0.5	cm	probe	attached	to	a	Branson	Sonifier	set	to	an	80%	duty	cycle,	output	setting	4,	30	second	duration.		Membranes	were	harvested	by	ultracentrifugation	at	100,000	x	g	for	30	minutes	at	4°C.		Supernatant	was	then	discarded	and	the	pellet	resuspended	in	1.2	L	MQ	H2O,	to	which	the	following	buffer	components	were	added:	20	mM	KPi	pH	7.0,	1	mM	EDTA,	2.5	mM	PMSF,	1%	tergitol)	and	stirred	for	2	hours	at	4°C.			
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	 In	 order	 to	 ensure	 purification	 of	 holo-cyt	 b5,	 the	 quantity	 of	 apo-cyt	 b5	 was	determined	and	a	10%	molar	excess	of	hemin	solution	(relative	to	apoprotein)	was	added	to	the	 lyase	 and	 stirred	 for	 10	 minutes	 at	 4°C.	 	 The	 insoluble	 fraction	 was	 removed	 by	ultracentrifugation	at	185,000	x	g	for	1	hour	at	4°C	and	the	supernatant	loaded	on	a	2.5	x	17	cm	DEAE	(DE-52)	column	equilibrated	with	DEAE	buffer	A	(25	mM	Tris	pH	8.0,	1	mM	EDTA,	10	mM	sodium	cholate)	and	eluted	with	a	linear	gradient	from	0-100%	DEAE	buffer	B	(DEAE	buffer	A	supplemented	with	0.4	M	NaCl).		Fractions	with	an	Rz	greater	than	1.6	were	pooled	and	purified	on	 a	Protein-Pak	DEAE	15HR	 (Waters)	 column	and	DEAE	buffers	described	previously	at	a	flow	rate	of	1.2	mL/min.		A	segmented	linear	gradient	was	employed	in	which	%	buffer	B	increased	from	0	to	40%	at	35	minutes,	then	to	100%	at	45	minutes.		Fractions	with	an	Rz	greater	than	2.8	were	pooled	and	rigorously	dialyzed	against	50	mM	potassium	phosphate,	 pH	 7.4.	 	 The	 final	 Rz	 was	 generally	 greater	 than	 3.5	 and	 concentration	 was	determined	using	e412	=	117	mM-1	cm-1.	
2.4.5	Expression	and	Purification	and	TEV	cleavage	of	MSP1D1	Membrane	scaffold	protein	was	expressed	and	purified	using	the	standard	protocol	described	in	detail	elsewhere.65		Following	purification,	the	poly-histidine	tag	was	removed	by	tobacco	etch	virus	protease	(TEV)	by	addition	of	1	mg	protease	to	100	mg	MSP1D1	in	the	presence	of	1	mM	DTT.		The	resultant	solution	incubated	at	30°C	until	complete	cleavage	of	the	histidine	tag	was	verified	by	either	MALDI-MS	or	SDS-PAGE.		The	excised	peptide	and	protease	 were	 subsequently	 removed	 from	 the	 MSP1D1-	 on	 a	 Ni-NTA	 column.	 	 Scaffold	protein	was	collected	as	flow-through	and	wash	using	buffer	containing	50	mM	TRIS	pH	7.2,	300	mM	NaCl,	50mM	Imidazole.	 	These	fractions	were	pooled,	concentrated,	and	dialyzed	rigorously	against	buffer	containing	100	mM	KPi,	pH	7.4	and	50	mM	NaCl.		
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2.5	Results	
In	 the	 initial	 phases	 of	 this	 dissertation,	 a	major	 goal	 involved	 leveraging	 of	 past	advances	 by	 combining	 established	 expression	 and	 purification	 methodologies	 with	optimization	of	codon	usage	for	E.	coli	 throughout	the	remainder	of	a	synthetic	gene,	and	incorporation	of	the	final	purified	product	in	Nanodiscs.		We	obtained	a	synthetic	gene	from	DNA	2.0	including	the	N-terminal	amino	acid	sequence	modifications	identified	by	Barnes	et	
al.	 with	 the	 remainder	 of	 the	 DNA	 sequence	 “optimized	 for	 E.	 coli	 expression”	 by	 a	proprietary	 process	 intended	 primarily	 to	 reduce	 usage	 of	 rare	 codons	 in	 E.	 coli.		Interestingly,	when	this	gene	was	subcloned	 into	a	pCWori+	construct	and	expressed	and	purified	as	described	by	Waterman57,	final	yields	of	CYP17A1	were	disappointingly	low,	at	roughly	 0.5	 mg	 P450/L.	 	 Ultimately	 co-transformation	 with	 the	 bacterial	 GroEL/ES	chaperone	 system	 was	 found	 to	 rescue	 expression	 levels	 to	 the	 values	 reported	 in	 the	literature,	 suggesting	 a	 misfolding	 pathway	 was	 operating	 with	 our	 synthetic	 construct,	though	no	efforts	were	made	to	experimentally	confirm	this	hypothesis.			Overexpression	of	chaperones	had	the	unexpected	consequence	of	the	co-purification	of	GroEL	 subunits	with	CYP17A1.	 	GroEL	 is	 a	 tetradecamer	 composed	of	 identical	 57	kD	subunits	which	form	a	structure	resembling	two	opposing	cups	joined	at	the	base.		Misfolded	proteins	 are	 targeted	 for	 refolding	 through	 association	with	hydrophobic	 patches	 on	 the	interior	 of	 the	 chaperone.66	 	 Presumably,	 hydrophobic	 regions	 of	 CYP17A1	 normally	associated	 with	 the	 membrane	 bilayer	 interact	 with	 GroEL	 in	 an	 analogous	 manner	 as	misfolded	 peptides.	 	 This	 interaction	 was	 resistant	 to	 disruption	 by	 typical	 purification	methods	such	as	use	of	detergents	and	high	salt	concentrations	and	has	been	observed	by	others	 during	 co-expression	 of	 chaperones	 and	 GST-tagged	 proteins.	 	 Fortuitously,	 the	
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ATP/Mg2+	dependent	conformational	changes	utilized	by	the	GroEL/ES	chaperones	can	be	triggered	 while	 CYP17A1	 is	 immobilized	 on	 a	 Ni-NTA	 column	 by	 inclusion	 of	 these	constituents	 in	wash	 buffer.67–69	 	 As	 the	 chaperone	 cycles	 through	 high	 and	 low	 affinity	states,	GroEL	may	be	washed	off	of	the	immobilized	CYP17A1,	yielding	electrophoretically	homogeneous	enzyme.	The	 last	 decade	 has	 witnessed	 incorporation	 of	 myriad	 membrane	 proteins	 into	Nanodiscs	 and	 evolution	 of	 a	 generalized	 protocol	 for	 this	 task.60,61	 	 A	 hallmark	 of	 these	established	methods	 is	 use	 of	 sodium	 cholate	 in	 the	 reconstitution	mixture,	 a	 detergent	compatible	 with	 most	 membrane	 proteins	 that	 readily	 solubilizes	 lipids	 and	 adsorbs	 to	hydrophobic	 beads.	 Cholate,	 though,	 was	 found	 to	 be	 incompatible	 with	 CYP17A1.		CYP17A1:Nanodiscs	prepared	with	 this	detergent	exhibited	a	peculiar	Soret	maximum	at	410	nm	and	were	 found	to	exist	primarily	 in	 the	P420	state.	 	 It	 is	unclear	whether	 these	effects	were	the	result	of	denaturation	or	if	cholate,	as	a	cholesterol	derivative	with	similar	structure	to	CYP17A1’s	native	substrates,	was	present	in	the	active	site	of	the	enzyme.			After	exhaustive	screening	Triton	X-100	was	identified	as	an	alternative	to	sodium	cholate	despite	 its	 slightly	 inferior	 ability	 to	 solubilize	 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine	(POPC)	and	adsorb	to	Amberlite	beads.	 	These	qualities	are	overcome	by	carefully	 controlling	 the	 ratio	 of	 POPC	 to	 Triton	 X-100	 and	 the	method	 described	 in	 the	following	 section	 is	 competent	 to	 produce	 stable,	 properly	 formed	Nanodiscs	 containing	POPC	 and	 a	 single	 CYP17A1	 in	 high	 yield	 (~20%	 of	 starting	 CYP17A1	 is	 successfully	incorporated).				
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Chapter	3:	Characterizing	the	Functional	
Properties	of	Wild	Type	and	T306A	CYP17A11	
3.1	Introduction	
In	the	human	adrenal	gland,	the	chemical	transformations	catalyzed	by	CYP17A1	are	highly	 compartmentalized	within	 the	 various	 regions	 of	 this	 organ.	 	 In	 the	adrenal	 zona	
fasciculata,	PREG	and	PROG	are	converted	into	their	respective	17a-hydroxy	products	via	a	CpdI	mediated	addition	of	an	alcohol	to	C17	of	the	steroid.		In	the	adrenal	zona	reticularis,	each	 of	 these	 hydroxylated	 products	 are	 converted	 to	 the	 estrogen	 and	 testosterone	precursors	dehydroepiandrosterone	(DHEA)	and	androstenedione	(AD)	via	17,20-carbon-carbon	bond	scission	in	which	the	21-carbon	17α-hydroxysteroids	are	cleaved	to	19-carbon,	17-ketosteroids,	 and	 acetic	 acid	 (Figure	3.1).30	Notably,	while	 the	hydroxylase	 activity	 of	CYP17A1	is	present	throughout	the	entire	lifespan	of	an	individual,	adrenal	production	of	androgens	is	initiated	only	at	andrenarche,	a	point	that	coincides	with	expression	of	cyt	b5	in	 the	 adrenal	 zona	 reticularis.70	 	 Both	 in	 vivo	 and	 in	 vitro	 experimental	 methods	 have	confirmed	a	substantial	stimulatory	effect	on	androgen	production	by	CYP17A1	when	cyt	b5	is	 present,	 with	 some	 laboratories	 reporting	 as	 much	 as	 a	 10-fold	 increase	 in	 DHEA	production.49,43,45,71		A	significant	limitation,	however,	in	previous	studies	has	been	lack	of	a	well-defined	 reconstitution	 system	 as	 other	 researchers	 have	 relied	 upon	 microsomal,	
																																																								
1	Portions	of	this	chapter	are	reprinted	with	permission	from	Khatri,	Y.,	Gregory,	M.	C.,	Grinkova,	Y.	V,	Denisov,	I.	G.	&	Sligar,	S.	G.	Active	site	proton	delivery	and	the	lyase	activity	of	human	CYP17A1.	Biochem.	
Biophys.	Res.	Commun.	443,	179–184	(2014).	
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detergent	solubilized,	or	soluble	experimental	modalities.		This	chapter	reports	in	detail	the	stimulatory	 effects	 of	 cyt	 b5	 in	 a	 Nanodisc	 system	 containing	 a	 POPC	 membrane	 and	controlled	stoichiometric	ratios	of	both	CPR	and	cyt	b5	to	CYP17A1.		 Additionally,	although	many	laboratories	have	characterized	the	catalytic	properties	of	 human	 CYP17A1,	 in	 addition	 to	 reliance	 on	 sub-optimal	 reconstitution	 systems,	 these	reports	have	generally	failed	to	evaluate	the	complete	set	of	substrates	(PREG,	PROG,	17-OH	PREG,	17-OH	PROG)	under	identical	conditions.		Given	the	dramatic	inconsistencies	in	Vmax	reported	 by	 various	 groups47,56,72,	 the	 problematic	 partitioning	 of	 these	 hydrophobic	substrates	 into	 detergent	 micelles,	 and	 the	 absence	 of	 any	 characterization	 of	 NADPH	oxidation	 during	 catalysis,	 these	 limitations	 have	 heretofore	 represented	 a	 severe	impairment	 in	 the	 ability	 to	 assess	 the	 influence	 of	 substrate	 structure	 on	 catalysis	 and	coupling	 efficiency.	 	 In	 order	 to	 address	 these	 deficiencies	 methods	 were	 developed	 to	quantitate	NADPH	oxidation	and	product	forming	rates	in	the	presence	of	all	substrates	with	precisely	 controlled	 stoichiometric	 ratios	 of	 CPR,	 cyt	 b5,	 and	 CYP17A1	 assembled	 into	Nanodiscs.								 These	baseline	data	are	subsequently	used	to	evaluate	the	properties	of	the	T306A	mutant	of	CYP17A1	possessing	an	impaired	acid/alcohol	pair	on	the	I-helix.		The	analogous	T252	residue	in	P450cam	is	known	to	play	an	essential	role	in	proton	transfer	essential	for	O-O	 bond	 scission	 required	 for	 CpdI	 formation	 and	 dioxygen	 activation	 during	 catalytic	turnover.73–75	 This	 residue	 forms	 part	 of	 the	 essential	 “proton	 shuttle”	 that	 delivers	 two	protons	 in	 rapid	 succession	 to	 the	 peroxo-ferric,	 and	 hydroperoxo-ferric	 intermediates,	respectively,	resulting	in	release	of	H2O	and	formation	of	CpdI.	 	Impairment	of	the	proton	delivery	pathway	via	introduction	of	a	hydrophobic	residue	in	this	position	has	been	shown	
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to	result	in	a	dramatic	inhibition	of	hydroxylation	of	camphor	despite	comparable	NADPH	consumption	 comparable	 to	 wild-type	 enzyme.76	 	 In	 such	 an	 impaired	 system	 electron	consumption	 is	nearly	 completely	uncoupled	 from	substrate	hydroxylation,	 and	 reducing	equivalents	instead	appear	in	released	hydrogen	peroxide.		Similar	results	are	reported	in	other	P450	systems	as	well,	including	P450BM3,	CYP2E1,	CYP2D6,	and	CYP1A2.77–81					 	The	 hydroxylase	 activity	 of	 CYP17A1	 is	 expected	 to	 proceed	 through	 the	 CpdI	initiated	hydrogen	abstraction	observed	in	other	members	of	the	P450	superfamily,	and	thus	the	T306A	mutant	was	expected	to	show	a	straightforward	decrease	in	product	formation	and	increase	in	uncoupling,	as	documented	in	other	P450	systems.		The	latter	C-C	scission	reactivity,	 however,	 is	 more	 circumspect	 and	 analysis	 of	 the	 product	 forming	 rate	 and	coupling	 of	 the	 T306A	 mutant	 offers	 the	 ability	 to	 differentiate	 between	 a	 CpdI	 or	peroxoanion	mediated	mechanism.	
3.2	Materials	and	Methods	
3.2.1	Design,	Expression,	and	Purification	of	Proteins	In	order	to	obtain	the	conserved	I-helix	variant	of	human	CYP17A1	T306A,	the	wild-type	pCWori_CYP17A1	construct	was	mutated	using	primers	5’-ggt	gcc	ggt	gtg	gaa	gcc	acc	acc	agc	gtc	gtc-3’	(forward)	and	5’-	gac	gac	gct	ggt	ggt	ggc	ttc	cac	acc	ggc	acc-3’	(Reverse).		The	sequence	of	the	mutant	was	verified	by	automated	DNA	sequencing	(ACGT,	Inc.).		T306A	CYP17A1	was	purified	in	an	identical	manner	as	described	for	wild	type	protein.		All	other	proteins	were	prepared	as	described	in	Chapter	2.	
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3.2.2	Spectral	Characteristics		 Spectral	 dissociation	 constants	 were	 determined	 by	 the	 sequential	 addition	 of	substrate	 dissolved	 in	 methanol	 to	 a	 cuvette	 containing	 1.5	 µM	 CYP17A1.	 	 Electronic	absorption	spectra	were	recorded	 from	350-800	nm	 in	a	Cary	300	spectrophotometer	at	25°C.		Spectral	dissociation	constants	were	estimated	by	plotting	the	change	in	the	peak	to	trough	 A390	 –	 A420	 difference	 spectrum	 versus	 substrate	 concentration	 and	 fitting	 the	resultant	binding	isotherm	to	the	quadratic	tight	binding	equation.		Spin	state	change	was	estimated	 using	 a	 singular	 value	 decomposition	 routine	 in	MATLAB	 to	 compare	 spectra	obtained	during	the	titration	relative	to	reference	spectra	representing	100%	high	and	low	spin	P450	forms.	
3.2.3	Reconstitution	System	and	Analysis	of	NADPH	Oxidation	Kinetics	Incorporation	of	CPR	into	preformed	and	purified	CYP17A1	(or	T306A)-Nanodiscs	was	 made	 by	 direct	 addition	 of	 CPR	 at	 1:4	 CYP17A1	 (or	 T306A)/CPR	 molar	 ratio,	 as	described	in	detail	by	Grinkova	et	al.	Briefly,	1	ml	of	CYP17A1	(or	T306A)	and	CPR	solution,	in	presence	or	absence	of	cyt	b5	(1:4:4	molar	ratio),	in	100	mM	potassium	phosphate	buffer,	pH	7.4,	containing	50	mM	NaCl	and	50	µM	substrate	(PROG,	17-OH	PROG,	PREG	or	17-OH	PREG)	was	brought	to	37°C	in	a	stirred	quartz	cuvette.	The	solution	incubated	for	5	min	and	the	reaction	 initiated	by	addition	of	NADPH	to	a	concentration	of	100	µM	(for	PREG	and	PROG)	or	300	µM	(17-OH	PREG	and	17-OH	PROG)	from	a	20	mM	stock	in	reaction	buffer.		The	rate	of	NADPH	consumption	was	determined	by	monitoring	the	decrease	in	absorbance	at	340	nm	using	an	extinction	coefficient	of	6.22	cm-1mM-1.		Each	reaction	was	quenched	by	addition	of	50	µl	of	9	M	sulfuric	acid	to	bring	the	pH	below	4.0.	The	sample	was	removed	
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from	the	cuvette,	flash	frozen	in	liquid	nitrogen,	and	stored	at	-80°C	until	product	analysis.	Optical	measurements	were	performed	on	a	Hitachi	U-3300	or	Cary	300	spectrophotometer	equipped	with	a	temperature	controller	and	magnetic	stirrer.		
3.2.4	Analysis	of	17-OH	PREG	Formation	Conversion	of	PREG	to	17-OH	PREG	was	determined	by	a	thin	layer	chromatographic	method.	Radiolabeled	[7-3H]	pregnenolone	(8.5	nmol,	0.8	µCi)	was	incubated	with	CYP17A1	or	T306A	(62	pmol)	incorporated	in	POPC	Nanodiscs,	CPR	(248	pmol)	and,	when	present,	cyt	b5	(235	pmol)	in	0.25	ml	of	0.1	M	potassium	phosphate	buffer,	pH	7.4,	containing	50	mM	NaCl	 for	10	min	before	 the	reaction	was	 initiated	by	addition	of	NADPH	(120	nmol).	The	reaction	proceeded	for	15	min	and	was	terminated	by	addition	of	2	mL	methylene	chloride.	The	mixture	was	vigorously	mixed	for	20	seconds	and	after	phase	separation	the	organic	layer	was	transferred	into	new	tube	and	the	solvent	evaporated	under	stream	of	nitrogen	gas.		The	sample	was	dissolved	in	30	µl	of	methanol	and	loaded	onto	TLC	plate	(EMD	TLC	Silica	gel	60	F254,	20X20	cm),	which	was	then	run	once	in	the	mixture	of	chloroform:	ethyl	acetate:	water	 (80:20:1).	Five-point	calibration	with	known	amounts	of	 radioactivity	was	performed	for	each	plate.	The	plate	was	 imaged	using	BAS-IP	TR	2025	imaging	plate	and	Storm	 840	 imaging	 system.	 The	 data	 were	 processed	 using	 Image	 J	 software	 to	 obtain	percent	conversion.	
3.2.5	Analysis	of	17-OH	PROG	Formation	Conversion	 of	 PROG	 to	 17-OH	 PROG	 was	 determined	 by	 reversed	 phase	 HPLC.		Briefly,	1	µl	of	a	27	mM	cortexolone	internal	standard	in	methanol	was	added	to	500	µl	of	each	reaction	sample	and	vortexed	for	10	sec.		2	mL	of	chloroform	was	added	to	each	sample	
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and	vortexed	for	30	seconds.	The	organic	phase	was	removed	and	dried	under	a	stream	of	nitrogen.	The	dried	sample	was	dissolved	in	100	µl	of	methanol	and	40	µl	was	injected	onto	C18-HPLC	column,	using	a	150	x	2.1	mm,	3µm	(ACE-111-1502)	with	a	mobile	phase	of	45%	each	of	methanol	and	acetonitrile	in	water	and	a	flow	rate	of	0.2	mL/min.	The	17-hydroxy	product	of	PROG	was	separated	in	a	linear	gradient	of	methanol	and	acetonitrile	from	20%	to	80%	in	28	min.	Peak	integration	was	performed	with	GRAM/32	software	(Thermo	Fischer	Scientific).					
3.2.6	Analysis	of	Androgen	Formation	DHEA	and	AD	were	analyzed	using	a	flame	ionization	discharge	detector	following	gas	chromatographic	separation.		Each	frozen	reaction	solution	was	thawed	and	800	µL	was	delivered	to	a	test	tube	and	steroid	product	separated	via	double	extraction	with	2	mL	of	dichloromethane	after	addition	of	a	progesterone	internal	standard.	The	organic	layer	was	dried	under	a	stream	of	nitrogen	and	the	extract	reconstituted	in	1.5	ml	of	80%	methanol.	The	 resultant	 lipemic	mixture	was	 further	 purified	 via	 a	 second	 separation	with	 750	µl	pentane,	 wherein	 lipids	 partition	 preferentially	 into	 the	 pentane	 layer.	 	 The	methanol/steroid	 solution	 was	 evaporated	 to	 dryness	 under	 vacuum.	 Steroids	 were	reconstituted	in	cyclohexane	and	analyzed	on	an	Agilent	6890	GC-FID	equipped	with	a	15	m	DB-1	column,	530	µm	I.D.,	1.5	µm	film	thickness	(J	&	W	Scientific).	Injector	temperature	and	volume	were	 250°C	 and	 3	µl.	 Nitrogen	 carrier	 gas	 was	 set	 to	 2.2	ml/min	 and	 the	 oven	temperature	was	held	at	100°C	for	1.5	min	and	ramped	to	275°C	at	30°C/min	and	held	for	13	min.		Data	analysis	was	performed	using	GRAM/32	AI	software.	
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3.3	Results	
3.3.1	Spectral	Properties	of	CYP17A1		 Both	 prenenolone	 and	 progesterone	 were	 found	 to	 bind	 Nanodisc	 incorporated	CYP17A1	 quite	 tightly,	 with	 spectral	 dissociation	 constants	 (Ks)	 of	 65	 nM	 and	 90	 nM,	respectively.		At	saturating	concentrations	both	substrates	caused	a	complete	conversion	to	the	high	spin	state.		Hydroxylated	substrates	had	substantially	higher	Ks	values	and	failed	to	completely	convert	the	enzyme	to	the	high	spin	state.	 	17-OH	PREG	was	found	to	bind	to	CYP17A1	with	a	Ks	of	0.77	µM	with	a	corresponding	value	of	0.98	µM	for	17-OH	PROG.		At	saturation,	both	substrates	resulted	 in	a	mixed	population	of	spin	states,	calculated	to	be	~60%	high	spin	for	both	17-OH	PREG	and	17-OH	PROG.		The	Soret	maximum	for	low	spin	ferric	 CYP17A1	was	 417	 nm.	 	 All	 substrates	 bound	 in	 a	 straightforward	 Type	 I	 manner	increasing	the	high	spin	population	with	a	Soret	at	393	nm.		In	the	presence	of	substrate,	the	enzyme	is	readily	reduced	to	the	ferrous	state	(408	nm)	by	sodium	dithionite,	and	addition	of	carbon	monoxide	saturated	buffer	results	in	the	immediate	formation	of	nearly	100%	of	the	P450	FeII:CO	state	at	447	nm	(Figure	3.2).				 Despite	spectra	reflective	of	the	“canonical”	P450s	in	the	ferric	state,	the	oxy-ferrous	spectrum	of	CYP17A1	exhibits	considerable	substrate	dependent	variability.		In	the	case	of	PROG	and	PREG,	Soret	maxima	were	consistent	with	other	P450	enzymes	at	421	nm	and	422	nm,	 respectively.	 	 However,	 formation	 of	 this	 transient	 species	 in	 the	 presence	 of	hydroxylated	substrates	results	in	a	red-shift	to	426	nm	with	17-OH	PROG	and	431	nm	in	the	presence	of	17-OH	PREG.	
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	 The	T306A	mutant	of	this	protein	exhibited	identical	behavior	to	the	WT	protein	in	the	ferric,	ferrous,	and	ferrous-CO	states.		Although	substrate	titrations	were	not	performed,	percent	conversion	to	the	high	spin	state	was	similar	to	wild-type	enzyme	and	saturation	occurred	at	<	10	µM	in	the	presence	of	all	substrates.			
3.3.2	NADPH	Oxidation	and	Product	Forming	Rates	of	WT	and	T306A	CYP17A1	Rates	 of	 pyridine	 nucleotide	 oxidation	 and	 product	 formation	were	measured	 for	both	wild	type	CYP17A1	and	the	T306A	mutant	in	the	absence	and	presence	of	a	4-fold	molar	excess	of	cyt	b5.		All	CYP17A1	mediated	reactions	were	evaluated	using	PREG,	PROG,	17-OH	PREG,	 and	 17-OH	 PROG	 as	 substrates.	 	 For	 the	 hydroxylation	 reaction	 the	 yield	 of	 17a-hydroxy	 product	 was	 quantitated.	 	 Due	 to	 the	 slow	 product	 forming	 rate	 and	 lack	 of	processivity	owing	to	substantially	higher	Kd	for	lyase	substrates,	androgen	formation	does	not	occur	under	the	experimental	conditions	described	above,	permitting	straightforward	analysis	of	product	forming	rates	for	this	first	step.		In	another	set	of	experiments	use	of	17-OH	PREG	and	17-OH	PROG	allowed	specific	examination	of	the	17,20-carbon-carbon	lyase	reaction	 of	 the	 corresponding	 substrates	 by	 monitoring	 production	 of	 DHEA	 and	 AD,	respectively.			 When	PREG	was	used	as	a	substrate,	the	wild	type	enzyme	formed	17-OH	PREG	at	a	rate	of	5.6	min-1	in	the	absence	of	cyt	b5	while	consuming	pyridine	nucleotide	at	5.8	min-1.		In	 the	presence	of	cyt	b5	product	 forming	rates	 increase	marginally	 to	6.2	min-1	(NADPH	oxidation	was	not	measured).		As	expected,	in	the	case	of	the	T306A	mutant,	17-OH	PREG	formation	 was	 substantially	 diminished,	 with	 rates	 of	 0.23	 min-1	 and	 0.35	 min-1	 in	 the	absence	and	presence	of	cyt	b5,	respectively.		NADPH	consumption	increased	dramatically,	to	38	min-1	in	reactions	containing	T306A	without	cyt	b5.		In	the	presence	of	PROG,	the	wild	
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type	 enzyme	 formed	 product	 at	 4.8	min-1	 consuming	NADPH	 at	 a	 rate	 of	 23	min-1.	 	 The	mutant	CYP17A1	showed	a	similar	expected	catalytic	impairment,	forming	17-OH	PROG	at	0.38	min-1	while	consuming	NADPH	at	a	rate	of	54	min-1.		These	results	are	summarized	in	Figure	3.3.			 In	a	separate	set	of	experiments,	the	lyase	activities	of	wild	type	and	mutant	CYP17A1	in	the	absence	and	presence	of	a	4-fold	molar	excess	of	cyt	b5	were	evaluated.		For	both	17-OH	PREG	and	17-OH	PROG,	the	presence	of	cyt	b5	significantly	enhanced	the	rate	of	product	formation,	from	0.15	min-1	to	0.76	min-1	for	17-OH	PREG	and	from	a	barely	detectable	0.05	min-1	to	0.34	min-1	for	17-OH	PROG.		Despite	the	large	changes	in	product	forming	rates,	only	minor	differences	in	NADPH	consumption	were	observed	upon	addition	of	cyt	b5.	 	Unlike	the	hydroxylase	activity,	T306A	CYP17A1	was	competent	to	catalyze	androgen	formation,	turning	over	17-OH	PREG	at	0.07	min-1	and	0.37	min-1	in	the	absence	and	presence	of	cyt	b5,	respectively.		Its	behavior	was	similar	when	given	17-OH	PROG	as	a	substrate,	generating	AD	with	rates	of	0.03	min-1	and	0.12	min-1	with	and	without	cyt	b5,	respectively.		In	another	departure	 from	 its	 behavior	when	 given	 hydroxylase	 substrates,	 NADPH	 oxidation	 rates	were	essentially	unchanged	during	 lyase	catalysis	relative	 to	 those	observed	 in	wild	 type	protein.		These	results	are	reported	in	Figure	3.4.		
3.4	Conclusions	
It	is	well	documented	that	cyt	b5	augments	the	17,20-carbon–carbon	bond	scission	of	mammalian	CYP17A1,	although	detailed	studies	as	a	function	of	the	P450:CPR:cyt	b5	ratio		in	their	full	length	forms	in	a	controlled	membrane	environment	have	not	been	reported.34	
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Therefore,	we	explored	the	effect	of	cyt	b5	during	lyase	activity	on	our	well	defined	assay	system	 consisting	 of	 CYP17A1	 Nanodiscs	 and	 co-incorporated	 CPR	 and	 cyt	 b5.	 We	unambiguously	observed	the	preference	of	17-OH	PREG	(>2-fold	higher	compared	to	17-OH	PROG)	during	17,20-lyase	activity	for	both	the	WT	and	T306A	in	presence	of	cyt	b5.	In	this	study,	we	also	observed	that	the	presence	of	cyt	b5	enhanced	the	lyase	activity	by	∼5-	and	7-fold	in	the	WT	and	∼5-	and	4-fold	in	the	T306A	mutant	for	17-OH	PREG	and	17-OH	PROG,	respectively.		We	observed	that	T306A	consumed	NADPH	at	15%	and	43%	faster	rates	than	WT	during	the	conversion	of	PREG	and	PROG	to	their	corresponding	17a-OH	product.		However,	the	product	formation	rates	were	dramatically	reduced	by	~94%	and	92%	respectively.	As	a	result,	the	coupling	efficiency	of	T306A	was	less	than	1%	during	the	hydroxylation	of	PREG	and	PROG,	compared	to	97%	and	22%,	respectively,	for	the	wild	type	enzyme.		These	two	conversions	 were	 highly	 uncoupled	 in	 which	 reducing	 equivalents	 and	 protons	 likely	funneled	into	formation	of	superoxide	and	hydrogen	peroxide	without	O-O	bond	cleavage	rather	than	productive	hydroxylation	of	the	substrates.	This	is	consistent	with	disruption	of	proton	delivery	to	the	distal	oxygen	atom	of	the	peroxoanion	required	to	initiate	O-O	bond	scission	and	formation	of	the	CpdI	reactive	intermediate.	These	results	are	comparable	with	previous	 investigations	 of	 P450cam,	 in	 which	 mutation	 of	 this	 critical	 residue	 severely	impairs	formation	of	CpdI	with	a	concomitant	decoupling	of	product	formation	from	NADPH	oxidation.73,82			Notably,	catalysis	of	carbon-carbon	bond	scission	by	the	T306A	mutant	was	largely	unimpeded	by	disruption	of	 the	CYP17A1	acid/alcohol	pair.	 	During	carbon-carbon	bond	scission	reaction	monitored	by	the	conversion	of	17-OH	PREG	to	DHEA,	the	rate	of	NADPH	
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oxidation	was	similar	(21	vs	17	nmol/min/nmol	P450)	for	WT	and	T306A,	respectively,	and	did	not	show	the	dramatic	difference	in	coupling	4%	vs	2%	for	WT	and	mutant.	Likewise,	the	lyase	reaction	of	17-OH	PROG	to	AD	also	showed	similar	rates	of	NADPH	oxidation	of	(26	vs	36	nmol/min/nmol	P450)	corresponding	to	coupling	of	1.3%	vs	0.3%	for	WT	and	T306A,	respectively	(Figure	3.5).	In	both	lyase	reactions,	we	did	not	observe	the	dramatic	changes	as	 during	 hydroxylase	 activity.	 Absence	 of	 significant	 ablation	 of	 catalytic	 activity	 and	constant	rates	of	NADPH	oxidation	in	this	experiment	are	inconsistent	with	results	observed	in	other	P450s,	where	a	functional	“proton	shuttle”	is	required	for	formation	of	the	active	oxidant	 CpdI.	 	 These	data	 support	 the	hypothesis	 that	 C-C	 lyase	 chemistry	 conducted	by	CYP17A1	 proceeds	 independently	 of	 O-O	 bond	 scission	 and	 CpdI	 formation,	 and	 are	consistent	with	expected	behavior	of	a	peroxoanion	intitiated	catalysis.			 	
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3.5	Tables	and	Figures	
													
Figure	3.1:	Compartmentalized	Steroid	Formation	in	the	Adrenal	Gland.	The	histological	slice	on	the	left	labeled	with	the	various	regions	of	the	adrenal	gland	with	the	corresponding	biological	transformations	performed	by	CYP17A1	on	the	right.		 	
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Figure	3.2:	Spectra	of	Pregnenolone	(P5)	Bound	CYP17A1	Nanodiscs.	Optical	spectra	of	CYP17A1	in	Nanodiscs	obtained	in	the	substrate	free	and	PREG	bound	states.		Ferric,	ferrous,	ferrous-CO,	and	oxy-ferrous	spectra	are	shown.	 	
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Figure	3.3:	Product	Formation,	NADPH	Oxidation,	and	Coupling	Efficiency	for	
Pregnenolone	and	Progesterone	Substrates.	Determination	of	steady	state	product	formation	(A),	and	NADPH	consumption	(B)	rate	of	PREG	and	PROG	catalyzed	by	WT	CYP17A1	and	the	T306A	mutant	are	shown.		Panel	C	indicates	coupling	efficiency	for	PREG	(D5)	and	PROG	(D4)	for	both	the	wild-type	and	mutant	CYP17A1.			 	
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Figure	3.4:	Product	Forming	Rates	for	17-OH	PREG	and	17-OH	PROG	Steady	state	product	forming	rates	when	17-OH	PREG	(A)	and	17-OH	PROG	(B)	are	used	as	substrates.		Black	bars	indicate	reactions	in	the	presence	of	a	4-fold	excess	of	cyt	b5,	white	bars	are	turnover	in	the	absence	of	cyt	b5.			 	
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Figure	3.5:	NADPH	Oxidation	and	Coupling	Efficiency	for	17-OH	PREG	and	17-OH	
PROG	NADPH	oxidation	(left	axis,	black	bar)	and	coupling	efficiency	(right	axis,	white	bar)	for	lyase	reactions	when	conducted	in	the	presence	of	4-fold	excess	of	cyt	b5.			 	
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Chapter	4:	Kinetic	Solvent	Isotope	Effect	During	
Lyase	Catalysis2	
4.1	Introduction	
	 As	 seen	 in	Figure	1.1,	 a	key	distinguishing	 feature	between	CpdI	and	peroxoanion	mediated	P450	catalysis	is	the	involvement	of	protons	in	scission	of	the	iron	ligated	dioxygen	bond	and	generation	of	the	ferryl	oxo	species.		The	necessity	of	at	least	two	protons	in	flight	to	 generate	 the	hydroperoxo	 and	 later	CpdI	 species	 suggests	 that	 kinetic	 solvent	 isotope	effects	 (KSIE)	 might	 be	 used	 to	 distinguish	 between	 a	 peroxoanion	 or	 CpdI	 active	intermediate.		Should	a	rate	limiting	step	exist	between	formation	of	the	peroxoanion	and	CpdI,	monitoring	steady	state	product	forming	rates	as	a	function	of	buffer	deuterium	oxide	content	could	exclude	one	of	the	two	potential	pathways.		In	the	case	of	a	CpdI	intermediate,	substitution	of	protium	oxide	with	D2O	would	be	expected	to	result	in	a	slowing	of	the	steady	state	product	forming	rate,	resulting	in	a	kH/kD	>	1.		Alternatively,	the	proton	independent	peroxo-	mediated	catalysis	should	exhibit	a	kH/kD	of	≤	1.83				 An	additional	concern	in	comparing	these	two	pathways	of	androgen	formation	are	uncoupling	reactions	which	release	hydrogen	peroxide:	the	“peroxide	shunt”	in	Figure	1.1.		As	described	in	Chapter	3,	the	hydroxylation	of	pregnenolone	(PREG)	at	the	17-position	is	well	coupled,	however	during	the	C-C	 lyase	17-OH	PREG	much	of	 the	pyridine	nucleotide	
																																																								
2	Portions	of	this	chapter	are	reprinted	with	permission	from	Gregory,	M.	C.,	Denisov,	I.	G.,	Grinkova,	Y.	V,	Khatri,	Y.	&	Sligar,	S.	G.	Kinetic	Solvent	Isotope	Effect	in	Human	P450	CYP17A1-Mediated	Androgen	Formation:	Evidence	for	a	Reactive	Peroxoanion	Intermediate.	J.	Am.	Chem.	Soc.	135,	16245–16247	(2013).		Copyright	2013	American	Chemical	Society.	
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reducing	 equivalents	 appear	 in	 free	 hydrogen	 peroxide	 rather	 than	 carbon	 product.84	Uncoupling	occurring	from	the	iron-peroxide	intermediates	can	also	involve	protons.	 	We	thus	have	the	following	branching	pathways	(Figure	4.1)	where	the	addition	of	two	protons	to	 the	 ferric	 peroxoanion	 [1]	 results	 in	 formation	 of	 CpdI	 which	 is	 utilized	 in	 the	hydroxylation	of	pregnenolone	[3]	to	17-OH	PREG	[4]	in	the	first	step	of	CYP17A1	catalysis.		The	 second,	 uncoupled	 step	 responsible	 for	 androgen	 formation,	 either	 proceeds	productively	 from	 [1]	 through	 an	 acyl-peroxo	 intermediate	 [5]	 to	 form	 DHEA	 [6],	 or	unproductively	through	proton	dependent	formation	of	[2]	and	ultimate	release	of	peroxide.		
4.2	Materials	and	Methods	
4.2.1	Protein	Expression	and	Purification	CYP17A1	in	Nanodiscs,	CPR,	and	cyt	b5	were	prepared	as	indicated	in	the	relevant	sections	of	Chapter	2.	
4.2.2	Turnover	Assays	Product	formation	and	NADPH	oxidation	rates	of	human	CYP17A1	incorporated	into	Nanodiscs	in	the	presence	of	its	redox	partner	cytochrome	P450	oxidoreductase	(CPR)	and	its	effector	cyt	b5	were	measured	in	the	presence	of	saturating	concentrations	of	PREG	(50	
µM)	and	17-OH	PREG	(50µM)	at	37°C	and	pH/pD	7.4.		Deuterated	samples	were	prepared	by	exhaustive	exchange	of	the	proteins	in	100	mM	KPi,	pH	7.4	D2O	buffer,	with	the	pH	meter	corrected	using	the	method	of	Glascoe	and	Long.85		The	17-OH	PREG	formation	assay	was	performed	as	indicated	in	Chapter	3.2..		DHEA	formation	was	quantitated	in	a	reconstituted	system	containing	208	pmol	CYP17A1	Nanodiscs	and	a	four-fold	molar	excess	of	cyt	b5	and	
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CPR	in	1.0	mL	of	100mM	potassium	phosphate,	pH/pD	7.4	containing	50	mM	NaCl	and	50	
µM	17-OH	PREG.		Reactions	were	carried	out	in	a	stirred	cuvette	in	a	temperature	controlled	Cary	300	spectrophotometer	and	monitored	at	340	nm	after	initiation	by	addition	of	600	nmol	NADPH.		Each	reaction	was	quenched	after	20	minutes	by	addition	of	50	µL	8.9	N	H2SO4.		Product	 analysis	 was	 performed	 using	 the	 gas	 chromatographic	 method	 described	 in	Chapter	3.2.6.		PREG	product	formation	was	assayed	as	described	in	section	3.2.4.				
4.3	Results	
	 When	 PREG	was	 used	 as	 a	 substrate,	 the	 rate	 of	 17a-hydroxy	 product	 formation	occurred	at	a	rate	of	22.6	±	0.9	min-1,	while	in	deuterated	buffer	this	rate	slowed	to	17.5	±	0.8	min-1.	This	corresponds	to	a	kinetic	solvent	isotope	effect	(KSIE)	for	the	hydroxylation	reaction	of		kH/kD	=	1.3,	very	similar	to	values	reported	for	other	P450	systems	catalyzing	hydroxylation	 chemistry.11,86,87	 	When	 17-OH	 PREG	was	 used	 as	 a	 substrate,	 the	 rate	 of	conversion	 of	 the	a-hydroxy	 ketone	 to	DHEA	 via	 C-C	 lyase	 activity	was	much	 slower,	 as	previously	described	in	Chapter	3.		Unexpectedly,	however,	when	D2O	was	substituted	for	H2O,	the	rate	of	product	 formation	with	this	substrate	was	dramatically	augmented,	 from	0.86	±	0.1			min-1	to	2.2	±	0.1	min-1.		This	corresponds	to	an	inverse	KSIE	of	0.39.		(Figure	4.2)	
 In addition to product formation, the overall rate of NADPH oxidation also monitors the 
uncoupling pathway.  In the case of the lyase activity when 17-OH PREG is a substrate, the 
majority of reducing equivalents appear as released hydrogen peroxide without substrate 
formation84.  Despite the inverse KSIE seen in the product forming rate, the rate of NADPH 
oxidation decreased by 40%, from 27.5 ± 0.6 min-1 to 16.6 ± 0.3 min-1.  This difference is also 
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reflected in turnover experiments conducted in the absence of substrate, where rates of NADPH 
oxidation in H2O and D2O were 31.5 ± 0.7 min-1 and 18.1±1.0 min-1, respectively. This normal 
slowing of rates in the presence of D2O versus H2O is another important indicator of the 
intermediates involved in lyase chemistry. The same rate decrease in D2O as compared to H2O in 
the substrate-free CYP17A1, reflecting NADPH oxidation in this system unrelated to product 
formation, suggests the same rate-limiting step for the overall steady-state NADPH consumption 
kinetics that is strongly dependent on protonation. This protonation step is likely to be the first 
protonation of peroxo-anion coordinated to the heme iron. An alternative suggestion of the second 
protonation event and formation of CpdI as the rate limiting step can be rejected as incompatible 
with the different signs of KSIE observed in hydroxylation of PREG and lyase reaction with 17-
OH PREG as substrate. If formation of CpdI would be the rate-limiting step, the KSIE of lyase 
reaction would be higher or equal to one, depending on the masking by other steps in the catalytic 
cycle.   	 	
4.4	Conclusions	
	 The	 hydroxylase	 activity	 of	 CYP17A1	 is	 expected	 to	 proceed	 through	 the	 classical	Groves	rebound	mechanism28	with	CpdI	as	the	reactive	intermediate.		Results	for	this	first	reaction	are	entirely	consistent	with	expectations	of	a	partially	masked,	proton	dependent,	CpdI	 mediated	 mechanism,	 and	 are	 congruent	 with	 previous	 reports	 of	 solvent	 isotope	effects	in	P450cam.11,87,88		The	large	inverse	isotope	effect	and	decrease	in	NADPH	oxidation	rate	for	the	latter	lyase	reaction	where	17-OH	PREG	is	subjected	to	17,20	C-C	bond	cleavage	to	form	DHEA,	however,	cannot	be	reconciled	with	a	CpdI	mediated	reaction.			Rather,	these	
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observations	are	consistent	with	inhibition	of	protonation	of	the	peroxo-ferric	species	in	a	manner	that	serves	to	facilitate	productive,	rather	than	unproductive	oxidation.	Formation	of	the	peroxo-ferric	intermediate	and	nucleophilic	attack	of	C-20	carbonyl	does	not	involve	any	 protonation	 event	 and	 is	 expected	 to	 exhibit	 the	 same	 kinetics	 in	 H2O	 and	 D2O.	Alternatively,	two	protonation	steps	with	concomitant	formation	of	the	hydroperoxo-ferric	complex	and	CpdI	progress	much	slower	in	D2O.	Because	of	this	difference	in	rates	between	productive	and	unproductive	pathways	at	the	peroxo-	branching	point	([1]	and	[2]	in	Figure	4.1)	the	steady-state	concentration	of	this	intermediate	[1]	increases	and	the	apparent	rate	of	product	formation	also	increases	in	D2O,	although	the	microscopic	catalytic	rate	of	[1]®	
[5]	is	the	same	in	both	solvents.	Such	mechanism	is	also	confirmed	by	significant	decrease	of	 NADPH	 consumption	 rate	 in	 D2O,	 indicating	 smaller	 fraction	 of	 reducing	 equivalents	following	proton-dependent	pathways	of	hydrogen	peroxide	formation	from	hydroperoxo-ferric	intermediate	and	oxidase	reaction	of	CpdI.	Similar	mechanistic	studies	in	other	enzymes	also	reported	inverse	solvent	isotope	effect	 as	 the	 result	 of	 slower	 uncoupling	 reaction	 that	 competed	 with	 the	 productive	pathway.	 This	was	 observed	 in	 tyrosine	 hydroxylase,	where	 uncoupling	 pathway	 via	 the	breakdown	of	peroxypterin	 intermediate	with	 formation	of	H2O2	can	be	compared	 to	 the	release	 of	 peroxide	 in	 cytochrome	 P450	 catalytic	 cycle	 and	 to	 uncoupling	 in	 flavin	monooxygenases.89,90	Another	example	of	improved	product	formation	in	steady-state	is	the	reaction	 catalyzed	 by	 putidamonooxin	 caused	 by	 considerable	 inhibition	 of	 uncoupling	channel	in	D2O	studied	by	Twilfer	et	al.91	In	this	work,	the	uncoupling	reaction	resulted	in	peroxide	release	and	thus	required	protonation.	In	D2O	this	protonation	was	significantly	slower	 and	 as	 a	 result,	 partitioning	 of	 the	 active	 intermediate	 between	 productive	 and	
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unproductive	pathways	was	shifted	in	favor	of	the	former.	This	example	of	directly	observed	competition	 between	 the	 productive	 (monooxygenase	 and	 dioxygenase	 reaction)	 and	unproductive	 (protonation	of	 active	oxygen	 species	 and	 formation	of	H2O2	 in	uncoupling	pathway)	pathways	of	this	enzyme	was	interpreted	as	indicating	the	iron-peroxo	complex	as	an	active	intermediate	in	putidamonooxin.		 The	normal	KSIE	for	hydroxylation	reaction	and	strong	inverse	apparent	KSIE	for	the	lyase	 reaction	 catalyzed	 by	 CYP17A1	 cannot	 be	 reconciled	 with	 the	 same	 rate-limiting	protonation	dependent	step	commonly	observed	in	other	cytochromes	P450	when	CpdI	is	the	 main	 catalytic	 intermediate.	 Rather,	 an	 inverse	 KSIE	 implies	 catalysis	 via	 a	 proton-independent	intermediate	and	the	presence	of	the	branching	proton-dependent	uncoupling	pathway,	which	is	considerably	slower	in	D2O,	thus	providing	higher	yield	of	the	product.	Taken	together,	these	results	suggest	two	distinct	mechanisms	for	the	first	and	the	second	steps	of	CYP17A1	catalyzed	reactions.				 These	 results	 highlight	 a	 novel	 property	 of	 the	CYP17A1	 active	 site:	 the	 ability	 to	select	between	use	of	multiple	reactive	intermediates	based	on	presence	of	a	17a-hydroxy	moiety	 on	 the	 substrate	 molecule.	 In	 the	 presence	 of	 pregnenolone,	 this	 enzyme	preferentially	 catalyzes	 formation	 of	 17-OH	 PREG	 in	 a	 straightforward	 CpdI	 mediated	mechanism	known	to	 function	 in	other	P450s.	 	However,	when	17-OH	PREG	 is	used	as	a	substrate,	our	observations	strongly	implicate	the	peroxoanion	as	the	reactive	intermediate.	
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4.5	Tables	and	Figures	
														
Figure	4.1:	Branch	Points	in	P450	Catalysis	17-OH	PREG	(4)	can	undergo	a	proton-independent	reaction	with	the	peroxoanion	(1),	forming	a	peroxo	hemiacetal	(5)	and	decomposing	to	androgen	product	(6).		Alternatively,	protonation	of	the	peroxoanion	forms	the	hydroperoxo	species	(2)	that	following	the	input	of	a	second	proton	can	be	release	non-productively	as	hydrogen	peroxide,	or	form	CpdI	to	hydroxylate	PREG	(3).			
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Figure	4.2:	Product	Forming	Rates	in	H2O	and	D2O	Left	panel	shows	the	rate	of	17-OH	PREG	formation	when	PREG	is	used	as	a	substrate.		Right	panel	shows	rate	of	DHEA	formation	when	17-OH	PREG	is	a	substrate.		Numbers	at	base	of	bars	represents	nmol	product/min/nmol	P450.			 	
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Chapter	5:	Resonance	Raman	Spectroscopy	of	
Ferric	and	Ferrous	CYP17A13	
5.1	Introduction	
	 As	 outlined	 in	 Figure	 1.2,	 the	 first	 reactions	 catalyzed	 by	 CYP17A1	 are	 17α-hydroxylation	 of	 PREG	 to	 17-OH	 PREG	 and	 PROG	 to	 17-OH	 PROG.	 These	 hydroxylated	products	 are	 then	 subjected	 to	 a	 second	 round	of	 catalysis	 generating	 the	DHEA	and	AD	androgens.34	 	 It	 is	 particularly	 notable	 that	 the	 relatively	minor	 structural	 differences	 in	these	substrates,	such	as	the	identity	of	the	C-3	substituent,	positioning	of	the	C=C	bond	(D4	vs	D5),	and	the	presence	of	a	17a-OH	exhibit	structurally,	kinetically,	and	mechanistically	distinct	interactions	with	this	enzyme.	 	As	defined	in	two	recent	publications	by	the	Scott	laboratory	 in	which	 the	 crystal	 structure	 of	 CYP17A1	was	 solved	 in	 the	 presence	 of	 the	inhibitor	 Abiraterone	 acetate	 and	 native	 substrates,	 the	 presence	 of	 either	 an	 alcohol	(PREG/17-OH	PREG)	or	a	keto	fragment	(PROG/17-OH	PROG)	can	have	profound	impact	on	the	positioning	of	these	molecules	in	the	active	site.92,93			 In	this	and	the	following	chapters,	 the	 impressive	power	of	resonance	Raman	(rR)	spectroscopy	 is	 employed	 to	 probe	 the	 heme	 environment	 of	 Nanodisc	 incorporated	CYP17A1.		Here,	rR	is	utilized	to	characterize	the	ferric	and	ferrous:CO	states	in	the	presence	of	the	native	substrates	of	this	enzyme.		Well	established	high	frequency	marker	modes	are																																																									
3	Portions	of	this	chapter	were	reprinted	with	permission	from	Mak,	P.	J.,	Gregory,	M.	C.,	Sligar,	S.	G.	&	Kincaid,	J.	R.	Resonance	Raman	Spectroscopy	Reveals	That	Substrate	Structure	Selectively	Impacts	the	Heme-Bound	Diatomic	Ligands	of	CYP17A1.	Biochemistry	53,	90–100	(2014).		Copyright	2014	American	Chemical	Society.		
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sensitive	 to	 changes	 in	oxidation	or	 spin	 state	of	 the	heme	 iron	atom	and	 low	 frequency	modes	 report	 changes	 in	 protein	 interactions	 with	 the	 heme	 periphery.94	 	 Particularly	important	in	these	stable	states	are	the	various	changes	to	propionic	acid	and	vinyl	heme	substituents	which	have	been	suggested	to	be	important	structural	determinants	of	heme	reactivity.95,96		Additionally,	Fe-S	and	Fe-C-O	modes	may	be	selectively	enhanced	providing	an	especially	sensitive	probe	of	these	key	linkages.97		 In	this	chapter	a	combination	of	Nanodisc	and	rR	spectroscopic	methods	are	utilized	in	the	interrogation	of	the	active	site	structure	of	CYP17A1	in	its	interaction	with	all	four	of	its	 native	 substrates.	 	 Low	 and	 high	 frequency	 spectra	 were	 collected	 in	 the	 ferric	 and	ferrous:CO	 states,	 the	 latter	 species	 being	 the	 accepted	 paradigm	 for	 probing	 distal	 and	proximal	effects	on	heme-bound	exogenous	ligands.			
5.2	Materials	and	Methods	
5.2.1	Preparation	of	Ferric	Samples	for	rR	Spectroscopy	Substrate	stock	solutions	containing	PROG,	17-OH	PROG,	PREG	and	17-OH	PREG	in	methanol	were	prepared	at	concentrations	of	8-10	mM.		CYP17A1	Nanodisc	solutions	in	100	mM	KPi,	 pH	7.4	 buffer	 containing	 15%	ultrapure	 glycerol	were	prepared	 as	 indicated	 in	Chapter	2.2.3	and	Chapter	2.3.		Solutions	were	concentrated	to	~100	µM	and	PROG	and	PREG	bound	 samples	 were	 prepared	 by	 the	 addition	 of	 the	 appropriate	 substrate	 to	 a	 final	concentration	of	400	µM.		The	17-OH	PROG-	and	17-OH	PREG	bound	samples	were	similarly	prepared	 by	 the	 addition	 of	 the	 appropriate	 substrate	 to	 500	 µM.	 	 Samples	 were	subsequently	flash	frozen	in	liquid	N2	before	further	use.		
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5.2.2	Preparation	of	Ferrous:CO	CYP17A1	Samples	A	100	μL	volume	of	~	100	μM	ferric	ND:CYP17A1	sample	in	a	septum-sealed	5	mm	NMR	 tube	 (WG-5	 Economy,	Wilmad)	was	 degassed	 by	multiple	 rounds	 of	 application	 of	vacuum	and	filling	with	argon	gas.	After	the	final	gas	evacuation,	the	CO	gas	was	introduced	to	the	NMR	tube	and	the	ferric	sample	was	reduced	by	addition	of	~2-5	molar	equivalents	(~2	μL)	of	sodium	dithionite	dissolved	in	freshly	degassed	100	mM	potassium	phosphate	buffer,	pH	7.4.	 	Formation	of	 ferrous	CO	adducts	was	confirmed	by	electronic	absorption	spectroscopy	in	the	Q	band	region.		Reduction	and	CO	saturation	was	deemed	complete	when	the	UV-Vis	spectra	of	these	samples	exhibited	a	single	Q	band	at	around	552	nm.	The	samples	contained	 no	 P420	 impurities	 as	 judged	 by	 the	 lack	 of	 bands	 near	 540	 nm	 and	 570	 nm	characteristic	for	ferrous	CO	adducts	of	P420.			
5.2.3	Collection	of	rR	Spectra	The	samples	of	ferric	CYP17A1	samples	were	measured	using	the	406.7	nm	and	356.7	nm	excitation	 lines	 from	a	Kr+	 laser	(Coherent	 Innova	Sabre	Ion	Laser)	and	the	Fe(II)-CO	adducts	were	excited	by	a	441.6	nm	line	provided	by	a	He-Cd	laser	(IK	Series	He-Cd	laser,	Kimmon	Koha	CO.,	LTD.).	The	rR	spectra	of	all	samples	were	measured	using	a	Spex	1269	spectrometer	equipped	with	Spec-10	LN-cooled	detector	(Princeton	Instruments).	The	slit	width	was	 set	 at	 100	 μm	 and	 the	 1200	 g/mm	 grating	was	 used.	 	With	 this	 grating,	 the	resultant	spectral	dispersion	 is	0.46	cm-1/pixel.	The	 laser	power	at	 the	 ferric	sample	was	adjusted	 to	 ~	 10	mW	while	 for	 ferrous	 CO	 adducts	 it	 was	 kept	 at	 ~1	mW	 to	minimize	photodissociation.	Moreover,	 to	 avoid	 laser-induced	heating	 and	protein	degradation	 the	samples	were	contained	in	spinning	NMR	tubes	(5	mm	outside	diameter,	WG-5	ECONOMY,	Wilmad).	The	180°	backscattering	geometry	was	used	for	all	measurements	and	the	laser	
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beam	was	focused	onto	the	sample	using	a	cylindrical	lens.	All	samples	were	measured	at	room	temperature.	Spectra	were	calibrated	with	fenchone	(Sigma-Aldrich,	WI),	toluene-2H6	and	acetone-2H6	(Cambridge	Isotope	Laboratories,	Inc.,	MA)	and	processed	with	Grams/32	AI	software	(Galactic	Industries,	Salem,	NH).			
5.3	Results	
5.3.1	High	Frequency	rR	of	the	Ferric	States	of	CYP17A1		 The	 spectrum	 of	 substrate-free	 ND:CYP17A1	 (Figure	 5.1,	 trace	 A)	 	 exhibits	characteristic	features	of	the	ferric	state:	the	ν4	oxidation	state	marker	is	observed	at	1372	cm-1.		Spin	state	marker	bands	ν3	at	1502	cm-1,	the	ν2	at	1581	cm-1	and	the	ν10	at	1636	cm-1,	are	indicative	of	a	pure	low	spin	6-coordinated	state,	reflective	of	the	expected	coordination	of	a	water	molecule	to	the	heme	iron.98,99		The	two	overlapped	features	observed	at	1621	cm-
1	and	1629	cm-1	are	assigned	 to	 the	ν(C=C)	stretching	modes	of	 the	 two	peripheral	vinyl	groups	with	respective	dispositions	in	and	out	of	the	planes	of	the	pyrrole	rings	to	which	they	are	bound,	consistent	with	previously	published	data.100			 Figure	5.1,	trace	B	with	PROG	bound	CYP17A1	shows	a	shift	in	spin	state	markers	to	1486	cm-1	(ν3),	1565	cm-1	(ν2)	and	1627	cm-1	(ν10),	 the	 last	overlapped	with	vinyl	v(C=C)	mode(s).	 	 These	 heme-core	 mode	 frequencies	 are	 consistent	 with	 a	 pure	 high	 spin	 5-coordinate	state.100,101				Consistent	with	UV-Vis	spectroscopy	reported	in	Chapter	3.3.1,	the	binding	of	17-OH	PROG	(Figure	5.1,	trace	C)	results	in	only	a	partial	spin	state	conversion,	as	indicated	by	the	presence	of	bands	characteristic	for	both	low	and	high	spin	states.		Similar	spectral	patterns	are	observed	for	the	PREG	and	17-OH	PREG	substrates,	as	seen	in	traces	E	
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and	 F	 of	 Figure	 5.1,	 where	 only	 partial	 spin	 state	 conversion	 is	 once	 again	 seen	 for	 the	hydroxylated	substrate.			 Partial	spin	state	conversions	upon	binding	of	certain	substrates,	such	as	the	17-OH	PROG	and	17-OH	PREG	samples	above,	have	been	observed	previously	for	other	cytochrome	P450	 enzymes,	 and	 is	most	 often	 attributed	 to	 incomplete	 expulsion	of	 the	distal	 pocket	water	cluster	and	coordination	of	a	residual	water	molecule.		However	in	this	case	it	must	be	noted	that	the	two	substrates	producing	partial	spin	state	conversions	possess	17a-hydroxy	substituents.		Based	on	crystal	structures	of	this	enzyme	in	the	presence	of	these	substrates,	it	is	expected	that	this	group	would	be	in	close	proximity	to	and	directed	towards	the	heme	iron.93		Therefore,	it	is	also	reasonable	to	suggest	that	these	R-OH	fragments	might	interact	directly	with	the	heme	iron.	Alternatively,	the	presence	of	this	R-OH	group	within	the	heme	pocket	might	enhance	retention	of	one	or	more	residual	water	molecules.		 Inasmuch	as	the	components	in	the	rR	spectra	that	are	associated	with	the	low	spin	state	do	not	significantly	differ	among	traces	A,C	and	F	(i.e.,	1636,	1581	and	1502	cm-1),	there	is	no	support	for	arguing	that	the	coordination	environment	is	different	for	the	substrate-free	(SF)	and	the	samples	bound	with	the	hydroxylated	substrates.	On	the	other	hand,	the	high	 degree	 of	 specificity	 associated	with	 the	 hydroxylation	 reactions	 and	 the	 relatively	crowded	 distal	 side	 pocket	 revealed	 in	 the	 crystal	 structure92,93	 tends	 to	 favor	 the	explanation	involving	direct	interaction	between	the	R-OH	and	heme	iron.	In	either	case	it	is	reasonable	to	suggest	that	the	retention	of	a	significant	amount	of	low	spin	form	for	the	17-OH	PROG	and	17-OH	PREG	substrates	is	directly	attributable	to	the	juxtaposition	of	the	17-OH	fragment	to	the	heme	iron.		
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	 Spin	 state	 populations	 for	 these	 five	 samples	 were	 estimated	 using	 a	 previously	determined	relative	rR	scattering	cross-sections	of	the	ν3	modes	for	the	low	spin	and	high	spin	 forms	 of	 cytochrome	 P450cam	 (CYP101)	 as	 described	 by	 	 Mak	 et	 al.102	 Using	 this	procedure,	the	substrate-free	enzyme	is	estimated	to	be	95%	LS,	whereas	the	HS	populations	of	the	PROG	and	PREG	bound	samples	are	calculated	to	be	94%	and	95%,	respectively.		On	the	other	hand,	the	HS	components	for	the	17-OH	PROG-	and	17-OH	PREG-bound	samples	are	calculated	to	be	59%	and	60%,	respectively.		These	values	are	in	good	agreement	with	UV-Vis	data	reported	in	Chapter	3.2.2.	
5.3.2	Low	Frequency	rR	of	the	Ferric	States	of	CYP17A1		 The	rR	spectra	in	the	low	frequency	region	provide	useful	information	not	only	on	the	binding	of	endogenous	and	exogenous	heme	axial	ligands,	but	also	on	the	disposition	of	the	heme	peripheral	groups	and	out-of-plane	distortions	of	the	heme	macrocycle	as	reflected	by	activation	of	out-of-plane	heme	modes.	 	Shown	in	Figure	5.2,	trace	A,	the	spectrum	of	the	substrate-free	sample	exhibits	a	single	feature	associated	with	the	propionate	bending	mode	(at	376	cm-1)	and	a	prominent	vinyl	bending	mode	at	424cm-1	along	with	a	weak	shoulder	at	414	cm-1.		Significantly,	addition	of	any	of	the	four	substrates	(Figure	5.2,	traces	B	through	E)	 causes	 no	 significant	 change	 in	 the	 frequencies	 of	 the	 376	 cm-1	mode,	 indicating	 that	hydrogen	 bonding	 to	 the	 propionate	 groups	 is	 not	 altered	 upon	 binding	 of	 any	 of	 these	substrates.	 Inspection	of	 the	 spectra	 in	 the	 vinyl	 bending	mode	 region	 indicates	 that	 the	prominent	mode	at	424	cm-1	is	not	altered.		While	there	appears	to	be	some	difference	in	the	weak	lower	frequency	modes	(414	vs	405	cm-1),	these	bands	are	of	low	intensity.		Though	substrate	binding	to	CYP17A1	causes	minimal	changes	in	bending	modes	of	the	peripheral	
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substituents,	there	is	clear	indication	of	activation	of	out-of-plane	(OOP)	modes	at	318,	~490	cm-1	and	816	cm-1,	assigned	to	the	γ7,	γ12	and	γ11	modes.		 Another	type	of	important	information	gleaned	from	the	low	frequency	region	of	the	rR	spectra	is	the	status	of	the	axial	ligands.	In	the	case	of	cytochromes	P450,	the	ν(Fe-S)	mode	is	effectively	enhanced	only	in	the	case	of	the	HS	ferric	form,	using	excitation	near	350	nm.	As	shown	in	Figure	5.3,	this	mode	is	observed	at	347	cm-1	for	all	substrates	used,	indicating	that	 substrate	 structure	does	not	 affect	 the	 trans-axial	 linkage	with	 the	 cysteine	 thiolate.	Note	that	the	apparent	diminished	intensities	of	the	ν(Fe-S)	modes	in	traces	B	and	D	are	a	result	of	normalization	with	the	ν7	mode	which	contains	contributions	from	the	substantial	remnants	of	the	LS	forms	in	these	two	samples.	The	main	point	to	be	made	here	is	that	any	changes	in	the	modes	associated	with	exogenous	axial	ligands,	such	as	the	CO	fragment	being	studied	here,	are	attributable	to	distal	side	interactions.		
5.3.3	Ferrous	CO	adducts	of	ND:CYP17A1	and	its	interaction	with	substrates			 The	ferrous	CO	adducts	of	cytochrome	P450	are	typically	exceptionally	stable	relative	to	 the	 oxy-complex.	 	 As	 such,	 ferrous	 carbonmonoxy	 forms	 are	 often	 exploited	 to	 probe	interactions	of	exogenous	axial	ligands	with	the	distal	heme	pocket	residues	and	substrates.		Changes	in	frequencies	and	intensities	of	modes	associated	with	the	Fe-C-O	fragment	reflect	the	strength	of	the	heme	linkage	with	the	proximal	endogenous	ligand	and	reliably	report	the	 steric	 and	 electronic	 influences	 presented	 by	 the	 distal	 pocket	 environment,	 such	 as	electrostatic	 or	 H-bonding	 interactions	 with	 distal	 pocket	 amino	 acid	 residues,	 water	molecules	or	substrates.	 	The	key	vibrational	modes	of	 interest	are	the	ν(Fe-C)	stretching	modes,	usually	observed	in	the	region	of	460-490	cm-1,	and	the	ν(C-O)	stretching	modes	seen	between	1920	 and	 1970	 cm-1.	 The	 δ(Fe-C-O)	 bending	modes,	 very	 often	 quite	weak	 and	
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difficult	 to	detect,	 are	 seen	 in	 the	 range	 from	550-570	cm-1.	A	well-documented	negative	linear	correlation	between	the	ν(C-O)	and	ν(Fe-C)	stretching	frequencies	arises	from	back	donation	of	the	Fe(II)	dπ	electrons	to	π*	orbitals	of	diatomic	ligands,	resulting	in	an	increase	of	the	Fe-C	bond	strength	while	weakening	that	of	the	C-O	bond.103,	104		 In	the	high	frequency	rR	spectra	of	the	CO-bound	ferrous	samples	the	ν4	oxidation	state	marker	band	of	all	 ferrous	CO	samples	 is	 located	at	1370	cm-1,	while	 the	spin	state	marker	bands,	the	ν3	and	ν2	modes,	are	seen	at	1497	cm-1	and	at	1585	cm-1,	respectively.		All	of	 these	 are	 characteristic	 for	 low	 spin	 6-coordinate	 CO	 adducts	 in	 accordance	 with	previously	published	data	on	other	cytochromes	P450.		Figure	5.3.3	shows	the	low	and	high	frequency	rR	spectra	in	the	regions	where	the	bands	associated	with	the	Fe-C-O	fragment	are	 observed.	 	 Binding	 of	 substrates	 to	 the	 ferrous	 CO	 form	 of	 Nanodisc-incorporated	CYP17A1	has	no	impact	on	the	heme	core	modes	nor	the	orientation	of	vinyl	groups,	based	on	 invariant	 frequencies	 in	 these	regions.	 	Once	more	 in	agreement	with	 the	data	 for	 the	substrate-bound	ferric	forms,	the	structural	differences	among	the	4	substrates	have	little	or	no	impact	on	the	heme	structure	or	its	interactions	with	active	site	residues.		 In	 the	spectrum	of	 the	substrate-free	 form	(Figure	5.3.3,	 trace	A,	 left	panel)	 in	 the	region	near	450-500	cm-1,	there	exists	a	broad	envelope	with	components	having	maxima	near	 472	 and	 485	 cm-1.	 This	 low	 frequency	 spectrum	 of	 the	 substrate	 free	 form	 shows	evidence	for	the	presence	of	two	Fe-C-O	conformers,	an	interpretation	that	is	confirmed	by	the	observation	of	two	ν(CO)	stretching	modes	in	the	high	frequency	region	(Figure	5.3.4,	trace	A,	right	panel).	Based	on	relative	intensities,	the	ν(C-O)	mode	at	1946	cm-1	corresponds	to	the	485	cm-1	ν(Fe-CO)	mode	and	the	1957	cm-1	feature	is	correlated	with	the	472	cm-1	ν(Fe-CO)	mode.	 	This	behavior	 is	consistent	with	 the	well-documented	 inverse	 frequency	
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relationship.103,104		The	only	remaining	point	to	be	noted	about	the	general	features	of	the	spectral	data	is	that	the	weak	bands	appearing	in	the	1840-1870	cm-1	region	are	well	fit	to	combination	modes	involving	the	ν(Fe-C)	and	ν4	modes.	Thus,	in	the	case	of	the	substrate-free	sample,	two	combination	modes	are	seen	near	1839	and	1852	cm-1	corresponding	to	(472	+1370	cm-1	and	485	+1370	cm-1),	while	the	combination	modes	for	the	other	 forms	occur	at	frequencies	about	15-25	cm-1	higher;	e.g.,	498	+	1370	cm-1	corresponds	to	1867	cm-
1	and	491	+	1370	cm-1	corresponds	to	the	broadened	combination	band	centered	at	1858	cm-1.	It	seems	important	to	emphasize	the	point	that	the	inherent	intensities	of	the	ν(C-O)	modes	are	quite	weak,	being	comparable	to	those	of	the	observed	combination	bands.		 Upon	 substrate	 binding	 substantial	 shifts	 in	 the	 internal	 modes	 of	 the	 Fe-C-O	fragment	occur.	The	samples	with	PROG	and	PREG	(traces	B	and	D)	exhibit	ν(C-O)	modes	at	1932	and	1940	cm-1,	 respectively,	 and	an	 identical	 frequency	of	498	cm-1	 for	 the	ν(Fe-C)	modes.	As	can	be	seen	by	inspection	of	the	inverse-correlation	plot	shown	in	Figure	5.6,	these	points	for	the	PROG	and	PREG	substrates	fall	along	the	line	generated	by	the	data	set	for	the	CYP17A1	samples	but	at	the	same	time,	there	is	a	clear	indication	that	unexpected	variations	occur	 inasmuch	 as	 these	 two	 substrates	 show	 identical	 ν(Fe-C)	 modes	 but	 ν(C-O)	frequencies	that	differ	by	8	cm-1.	Large	shifts	of	the	internal	modes	of	the	Fe-C-O	fragment	upon	 substrate	 binding	 are	 characteristic	 for	 enzymes	 with	 relatively	 small	 and	 tightly	organized	heme	pockets.	 	 Substrate	associated	shifts	 to	higher	 frequency	of	 the	ν(Fe-CO)	mode	of	20-25	 cm-1	magnitude	were	previously	observed	 in	bacterial	 cytochrome	P450s	such	as	cytochrome	P450cam	(CYP101).98	On	the	other	hand,	in	the	case	of	mammalian	drug-metabolizing	 cytochromes	 P450,	which	 have	 larger	 and	 relatively	 flexible	 heme	 pockets,	addition	of	substrates	typically	causes	minimal	changes	in	the	ν(Fe-CO)	frequency	(<5	cm-
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1).104	 	 The	 δ(Fe-C-O)	 bending	 modes	 for	 substrate-bound	 samples	 are	 upshifted	 3	 cm-1	relative	 to	 the	 bending	 mode	 seen	 in	 substrate-free	 sample,	 consistent	 with	 the	 higher	frequencies	of	the	Fe-CO	stretching	modes.			 In	 the	 case	 of	 the	 17a-hydroxy	 substrates,	 this	 alcohol	 is	 expected	 to	 occupy	 a	position	where	interaction	with	the	Fe-C-O	fragment	is	possible,	Spectral	data	obtained	for	the	17-OH	PROG	bound	sample	reveals	only	one	ν(Fe-C)	and	one	ν(C-O)	mode,	appearing	at	491	and	1938	cm-1,	data	that	are	consistent	with	a	single	Fe-C-O	conformer.	Additionally,	the	Fe-CO	 associated	 modes	 in	 the	 17-OH	 PROG	 bound	 spectra	 are	 relatively	 narrow;	 an	observation	that	likely	reflects	a	highly	directional	H-bonding	interaction	between	the	Fe-CO	fragment	and	the	17-OH	PROG	substrate	that	restricts	the	degree	of	 fluctuation	of	the	fragment	within	the	pocket.			 In	 contrast	 with	 the	 relatively	 straightforward	 spectral	 data	 obtained	 for	 17-OH	PROG,	the	spectra	obtained	in	the	presence	of	17-OH	PREG	is	extremely	complex	(Figure	5.4,	trace	E).			In	the	low	frequency	region	features	are	seen	at	481	and	505	cm-1,	with	indications	of	a	weak	shoulder	near	522	cm-1.	Carefully	conducted	rR	studies	of	the	region	containing	the	ν(C-O)	stretching	modes	near	1900-1950	cm-1	shows	only	two	features	attributable	to	ν(C-O),	occurring	at	1953	and	1928	cm-1;	based	on	relative	intensities	the	higher	frequency	mode	correlates	with	the	481	cm-1	feature	with	the	other	forming	the	505/1928	cm-1	pair.		Given	the	fact	that	only	two	ν(C-O)	modes	were	observed	and	the	relative	weakness	of	the	shoulder	near	522	cm-1,	spectra	were	also	acquired	using	13C16O	in	an	effort	to	clarify	the	three-component	envelope.			 Figure	5.5,	shows	rR	spectra	of	the	12C16O	and	13C16O	substituted	ferrous	CO	adducts	in	the	low	frequency	region	and	their	difference	pattern.	The	analysis	of	the	difference	trace	
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is	not	straightforward	because	the	isotopic	shifts	are	smaller	than	the	bandwidths	and	as	result	the	peaks	seen	in	difference	trace	represent	frequencies	of	the	bands’	wings	instead	of	true	frequencies	of	Fe-C	stretches.	In	order	to	extract	the	frequencies	of	these	unresolved	Raman	bands,	the	absolute	spectra	were	deconvoluted	in	the	region	of	430-610	cm-1	with	50/50	%	Gaussian/Lorenzian	functions.	The	ν(Fe-C)	envelope	of	12C16O	spectrum	was	best	fitted	with	three	bands	at	481	cm-1,	505	cm-1	and	522	cm-1;	attention	was	given	mainly	to	the	ν(Fe-CO)	stretching	modes,	since	the	region	containing	the	weak	δ(Fe-C-O)	bending	modes,	as	well	 as	 several	weak	heme	modes,	was	not	 sufficiently	 enhanced	 to	properly	 treat	 by	deconvolution.	 A	 similar	 procedure	 was	 applied	 to	 the	 13C16O	 spectrum,	 where	 it	 was	indicated	that	the	Fe-C	associated	modes	were	shifted	by	4	cm-1	to	lower	frequency	(to	477	cm-1	and	501	cm-1),	while	the	band	at	522	cm-1	did	not	shift.	It	is	noted	that	a	heme	mode	is	observed	at	this	frequency	in	the	spectra	obtained	for	many	LS	ferric	forms	and	the	other	CO	adducts	studied	here.			 Even	though	binding	of	17-OH	PREG	to	CYP17A1	gives	rise	to	a	mixture	of	two	Fe-C-O	conformers,	these	data	observed	yield	a	well	behaved	inverse	linear	correlation,	as	shown	in	Figure	5.6.	This	 figure	shows	a	negative	correlation	between	ν(Fe-C)	and	ν(CO)	for	the	Nanodisc-incorporated	 CYP17A1	 samples	 investigated	 here	 (red	 triangles	 and	 red	 line),	along	 with	 similar	 plots	 for	 other	 previously	 reported	 bacterial	 and	 mammalian	cytochromes	 P450	 and	 for	 mammalian	 forms	 of	 nitric	 oxide	 synthase	 (NOS),	 another	thiolate-ligated	heme	protein.			 It	is	generally	accepted	that	the	slopes	of	such	correlations	are	mainly	determined	by	distal	pocket	polarity	with	positive	electrostatic	potentials	often	associated	with	H-bonding	shifting	the	points	to	the	upper	left,	reflecting	enhanced	Fe	dπ	à	π(CO)	back-bonding.97	The	
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position	of	 such	plots	 along	 the	 vertical	 axis	 is	 influenced	by	 the	 relative	 strength	of	 the	donor	ability	of	the	trans-axial	heme	ligand;	e.g.,	the	line	for	histidine-ligated	heme	is	shifted	vertically	to	higher	regions	than	the	lines	shown	in	Figure	5.6		The	 thiolate	 in	 P450cam	 (CYP101)	 has	 three	 backbone	 hydrogen	 bonds	 from	NH	groups	of	nearby	amides,	yielding	an	Fe-S	bond	that	exhibits	a	ν(Fe-S)	mode	near	~353	cm-
1.51	The	point	in	the	lower	right	of	the	P450cam	line	represents	the	substrate-free	state	and	the	points	to	the	higher	left	side	are	associated	with	the	substrate-bound	states.	The	CYP101	substrates	bind	close	to	the	heme	iron,	expelling	water	molecules	from	the	heme	pocket	and	allowing	 the	CO	 ligand	 to	directly	 interact	with	H-bond	donor	 groups,	which	 involve	 the	D251	and	T252	residues	and	possibly	their	associated	water	molecules.		These	residues	are	postulated	to	play	a	central	role	in	proton	shuttle	required	for	O-O	cleavage.	The	NOS	data	fall	on	a	separate	ν(Fe-C)/ν(CO)	line	that	is	much	higher	than	that	for	cytochrome	P450cam,	owing	to	weakening	of	the	Fe-S	linkage.	The	heme-bound	thiolate	of	NOS	has	only	two	H-bonds	from	backbone	NH	groups,	but	more	importantly,	it	is	involved	in	one	H-bond	from	a	tryptophan	sidechain	residue.	This	stronger	H-bond	was	shown	to	weaken	the	thiolate	donor	strength,	as	reflected	in	a	lower	ν(Fe-S)	mode	(~340	cm-1)	relative	to	CYP101.	The	result	of	this	weakened	trans-axial	bond	leads	to	increases	in	the	opposing	Fe-C	bond	strength	(and	ν(Fe-C)	 frequency),	 raising	 the	 back-bonding	 correlation	 line	 above	 that	 of	 cytochrome	P450cam.		Considering	 all	 of	 the	 data	 acquired	 for	 CYP17A1,	 two	 aspects	 of	 the	 derived	correlation	need	to	be	addressed.	First,	it	is	noted	that	the	points	generally	fall	above	those	obtained	for	the	CYP101,	an	observation	that	is	entirely	consistent	with	the	weakened	Fe-S	bond	with	its	ν(Fe-S)	mode	near	347	cm-1	as	documented	in	Figure	5.3.3,	versus	the	value	of	
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353	cm-1	reported	for	CYP101.51	A	secondary	observation	was	that	the	slope	of	the	derived	line	obtained	for	CYP17A1	is	significantly	greater	than	those	for	the	other	two	sets	of	data.	One	cause	of	this	might	be	that	the	number	of	data	points	is	insufficient	to	generate	a	valid	correlation;	however,	the	number	of	points	for	the	CYP101	and	NOS	plots	is	not	substantially	larger,	yet	both	yield	comparable	slopes.	Alternatively,	it	seems	plausible	that	the	active	site	structural	organization	for	steroidogenic	cytochromes	P450	might	be	relatively	more	rigid,	as	reflected	by	the	strict	requirements	for	a	high	degree	of	stereospecificity	attending	the	chemical	 conversions	 which	 they	 orchestrate.	 Thus,	 the	 presence	 of	 specific	 functional	groups	on	the	substrate	periphery	might	introduce	highly	directional	steric	or	electrostatic	interactions	that	lead	to	a	greater	slope	and/or	deviations	of	some	points	(substrates)	from	the	 typical	 plots	 that	 are	 determined	 by	 more	 remote	 or	 delocalized	 electrostatic	interactions.		Figure	5.5	also	shows	the	dramatically	different	behavior	exhibited	 for	 the	sample	containing	17-OH	PREG.	 Like,	 17-OH	PROG	 it	 introduces	 into	 the	heme	distal	 pocket	 the	highly	polar	R-O-H	functionality,	yet	the	spectral	differences	are	quite	remarkable	with	the	17-OH	PREG	substrate	giving	rise	to	two	Fe-C-O	conformers.	One	conformer	(point	9)	gives	spectral	parameters	similar	to	those	seen	for	the	two	substrate-free	forms	(points	8	and	10)	and	is	comparably	broad,	most	likely	reflecting	a	conformer	that	is	weakly	H-bonded	to	distal	pocket	 residues	or	 loosely	associated	water	molecules.	A	 second	conformer	 (point	14)	 is	positioned	 nearer	 to	 the	 points	 observed	 for	 the	 other	 three	 substrates,	 but	 apparently	experiencing	a	stronger	electropositive	field	that	the	other	three;	i.e.,	lying	higher	to	the	left	along	the	line.			
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5.4	Conclusions	
	 The	 rR	 spectral	 data	 acquired	 here	 reveal	 key	 information	 regarding	 the	substrate/protein	interplay	associated	with	the	substrate	binding	event	that	can	affect	the	active	site	structure	and	reactivity.	Careful	analysis	of	the	data	acquired	for	the	ferric	forms	show	that	binding	of	substrate	causes	variable	degrees	of	conversion	from	the	low	spin	to	high	spin	state,	with	the	non-hydroxylated	PROG	and	PREG	yielding	almost	complete	high	spin	form,	while	the	two	hydroxylated	substrates	give	only	about	a	60%	conversion	to	HS.	This	 incomplete	 conversion	 is	 attributable	 to	 either	 a	 direct	 interaction	 of	 the	 17-OH	fragment	with	the	heme	iron	or	possibly	retention	of	an	active	site	water	molecule	that	can	interact	with	 the	heme	 iron.	Another	 important	 result	 from	 the	present	 study	 is	 that	 the	acquired	rR	spectra	of	the	ferric	HS	forms	as	well	as	the	ferrous	CO	adducts,	show	that	the	heme	structure	and	its	interactions	with	the	active	site	protein	residues	remain	constant	for	all	four	substrates.		The	heme	group	in	CYP17A1	is	thus	held	in	a	relatively	fixed	orientation	with	 respect	 to	 the	 associated	 protein,	 remaining	 unaffected	 by	 any	 differences	 in	 the	molecular	structure	of	these	four	substrates.			 An	 important	corollary	to	the	above	finding	 is	 that	any	differences	encountered	 in	enzymatic	 processing	 of	 these	 four	 substrates	 are	 most	 reasonably	 attributed	 to	 subtle	alterations	in	the	intermolecular	interactions	of	a	given	substrate	with	the	associated	heme	distal	axial	ligand.		Within	the	natural	enzymatic	cycle	this	would	include	the	bound	dioxygen	ligand,	its	reduced	peroxo-	or	hydroperoxo-	forms,	or	any	species	arising	from	an	O-O	bond	cleavage	process,	such	as	the	CpdI	intermediate.	In	the	present	work,	the	exogenous	heme	ligand	 is	 CO	 and,	 the	 largest	 changes	 in	 the	 rR	 spectra	 acquired	 for	 the	 four	 different	substrates	 occur	 for	 the	 internal	 modes	 of	 the	 Fe-C-O	 fragment.	 The	 most	 intriguing	
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observation	is	the	appearance	of	two	Fe-C-O	conformers	for	the	sample	containing	17-OH	PREG,	because	it	might	have	been	expected	that	the	presence	of	the	17-OH	fragment	also	would	give	rise	to	two	conformers	for	the	sample	containing	17-OH	PROG.		The	important	functional	 implication	 of	 this	 is	 that	 the	 subtle	 difference	 between	 the	 –OH	 and	 -C=O	substituents	at	the	remote	3β-position	of	the	17-OH	PREG	and	OH	PROG,	respectively,	can	significantly	alter	the	interaction	of	the	17-OH	group	with	the	Fe-C-O	fragment.	While	this	difference	in	substrate	disposition	may	lead	only	to	disorder	for	the	weakly	H-bonding	Fe-C-O	fragment,	its	effects	could	be	enhanced	with	more	strongly	H-bonding	fragments,	including	Fe-O-O.											
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5.5	Tables	and	Figures	
																
Figure	5.1:	High	Frequency	Spectrum	of	Ferric	CYP17A1	High	frequency	rR	spectrum	of	ferric	CYP17A1	in	the	substrate	free	state	(A)	and	with	PROG	(B),	17-OH	PROG	(C),	PREG	(D),	and	17-OH	PREG	(E).		 	
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Figure	5.2:	Low	Frequency	Spectra	of	Ferric	CYP17A1	Low	frequency	rR	data	of	ferric	CYP17A1	in	substrate	free	state	(A)	and	with	PROG	(B),	17-OH	PROG	(C),	PREG	(D),	and	17-OH	PREG	(E)					 	
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Figure	5.3:	Low	Frequency	Spectra	of	CYP17A1	(356.7	nm	Excitation)	Low	frequency	rR	data	of	ferric	CYP17A1	with	PROG	(A),	17-OH	PROG	(B),	PREG	(C),	17-OH	PREG	(D).		Excitation	laser	lie	was	356.7	nm.		 	
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Figure	5.4:	rR	Spectra	of	Ferrous:CO	States	Low	frequency	(left	panel)	and	high	frequency	(right	panel)	rR	data	of	ferrous	CO	adducts	of	substrate	free	CYP17A1	(A)	and	with	PROG	(B),	17-OH	PROG	(C),	PREG	(D),	17-OH	PREG	(E).					 	
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Figure	5.5:	Deconvolution	of	17-OH	PREG	Fe-CO	Spectra	Experimental	spectra	of	 the	 ferrous	12C16O	(A)	and	the	13C16O	adducts	of	17-OH	PREG	bound	 CYP17A1	 (B)	 and	 their	 difference	 trace.	 	 The	 thin	 black	 lines	 represent	 fitted	50%/50%	Gaussian/Lorenzian	functions	and	their	bandwidths	are	shown	in	parentheses.		 	
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Figure	5.6:	Backbonding	Correlation	Plot	Diagrams	 showing	 an	 inverse	 correlation	 for	 CYPs	 and	 NOSs.	 	 The	 numbers	 represent	proteins	 listed	 in	 Supplemantary	 Table	 S1.	 	 The	 green	 squares	 show	 points	 for	 CYP101	(green	line),	the	red	triangles	show	points	for	CYP17A1	(red	line),	and	the	blue	diamonds	for	mammalian	NOS’s	(blue	line).		 	
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Chapter	6:	Resonance	Raman	Spectroscopy	of	the	
CYP17A1	Oxy	Complex4	
	
6.1	Introduction	
	 Proceeding	 “forward”	 through	 the	 P450	 catalytic	 cycle,	 this	 chapter	 documents	experiments	 characterizing	 the	 disposition	 of	 the	 oxy-complex	 in	 the	 presence	 of	 PREG,	PROG,	17-OH	PREG,	and	17-OH	PROG.		Formed	by	binding	molecular	oxygen	to	the	ferrous	heme	iron,	this	is	the	last	quasi-stable	intermediate	that	can	be	generated	with	conventional	methods	and	without	the	use	of	unnatural	oxidants	such	as	m-Chloroperoxybenzoic	acid.24		Interest	in	the	nature	of	the	oxy-complex	is	multifaceted	as	the	bound	dioxygen	may	be	used	as	a	probe	of	the	heme	environment	in	an	analogous	manner	as	CO	in	the	preceding	chapter.		Importantly,	while	CO	adopts	a	linear	arrangement	with	respect	to	the	heme	plane,	dioxygen	exists	in	a	“bent”	orientation	that	persists	following	formation	of	the	peroxo-	species.		Thus	it	is	an	easily	accessible	state	expected	to	reliably	report	conditions	likely	to	be	encountered	in	 later	 fleeting	 peroxo	 and	 hydroperoxo	 intermediates.	 	 Finally,	 the	 amenability	 of	 this	intermediate	 to	 interrogation	 by	 rR	 spectroscopy	 is	 well	 documented	 in	 a	 variety	 of	P450s.105–109		
																																																								
4	Portions	of	this	chapter	were	reprinted	with	permission	from	Gregory,	M.,	Mak,	P.	J.,	Sligar,	S.	G.	&	Kincaid,	J.	R.	Differential	Hydrogen	Bonding	in	Human	CYP17A1	Dictates	Hydroxylation	versus	Lyase	Chemistry.	Angew.	
Chemie	52,	5342–5345	(2013)	
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	 As	documented	in	previous	chapters,	the	minute	structural	differences	between	the	four	 native	 substrates	 of	 CYP17A1	 substantially	 vary	 binding	 properties,	 turnover,	 and	positioning	of	 the	 substrate	 in	 the	heme	environment.	 	 In	order	 to	determine	how	 these	structural	elements	contribute	to	the	highly	regio-	and	sterospecific	reactions	catalyzed	by	CYP17A1	it	is	essential	to	evaluate	the	nature	of	the	later	intermediates	in	the	catalytic	cycle.		Especially	intriguing	is	the	roughly	50-fold	preference	of	CYP17A1	for	17-OH	PREG	versus	17-OH	PROG	 in	 terms	of	 kcat/Km	 that	drives	human	 steroidogenic	 flux	 almost	 exclusively	through	the	17-OH	PREG	to	DHEA	pathway.43,71,110,111				 Clearly,	elucidating	the	factors	that	control	CYP17A1	product	formation	is	crucial	for	understanding	healthy	and	diseased	human	physiology.			Additionally,	particularly	intense	scrutiny	of	the	C-C	lyase	activity	of	this	enzyme	has	led	to	suggestions	that	nucleophilic	attack	on	the	C-20	carbonyl	by	the	early	peroxo-ferric	intermediate	is	utilized	in	the	formation	of	androgens.50	 	Therefore	it	 is	 important	to	define	structural	 features	of	the	active	site	that	could	 control	 a	 branch	point	 between	O-O	bond	 scission/CpdI	 formation	 verses	 a	 heme-oxygen	intermediate	reactive	in	C-C	lyase	chemistry.		 An	 important	 step	 towards	 the	 understanding	 of	 androgen	 formation	 were	 the	recently	reported	crystal	structures	by	the	Scott	laboratory	of	human	CYP17A1	in	complex	with	 promising	 anti-cancer	 drugs,	 and	 in	 the	 presence	 of	 native	 substrates.92,93	 These	authors	 used	 molecular	 modeling	 to	 suggest	 that	 interactions	 of	 the	 3β-alcohol	 or	corresponding	 ketone	 fragments	 of	 PREG	 and	 PROG	with	 active	 site	H-bonding	 residues	position	 the	 substrate	 in	 correct	 orientation	with	 respect	 to	 the	 heme	 prosthetic	 group.		However,	 they	 also	 express	 that	 active	 site	 topology	might	 be	 altered	 by	 substrates	 and	stressed	the	pressing	need	for	further	experimental	work.		
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	 The	 Nanodisc	 system,	 which	 allows	 functional	 incorporation	 of	 these	 membrane	proteins	into	homogenous	and	monodisperse	membrane	environments,	yields	exceptionally	well-behaved	 ligand	 binding	 properties,	 as	 evidenced	 by	 clean	 conversions	 of	 spin-state	populations,	and	also	enhances	stability	of	their	dioxygen	adducts.58,112,113	Combination	of	this	system	with	the	power	of	resonance	Raman	(rR)	spectroscopy	to	interrogate	active	site	structure	in	heme	proteins	presents	an	especially	effective	approach	to	explore	the	complex	mechanism	of	CYP17A1.	Specifically	addressed	 in	 this	 chapter	 is	a	particularly	 intriguing	aspect	of	CYP17A1	structure,	wherein	 the	choice	of	 substrate	controls	hydrogen	bonding	that	 defines	 the	 catalytic	 channel	 for	 product	 formation.	 	 Here	 it	 is	 shown	 that	 rR	spectroscopy	demonstrates	that	the	single	difference	at	the	3β	position	of	17-OH	PREG	and	17-OH	PROG	leads	to	unequivocal	changes	in	active	site	H-bonding	interactions	with	the	key	Fe-O-O	 fragment	of	enzymatic	 intermediates	 leading	to	alterations	 in	electronic	structure	that	then	control	substrate	processing.			
6.2	Materials	and	Methods	
6.2.1	Protein	Expression,	Purification,	and	Nanodisc	Incorporation	of	CYP17A1	CYP17A1	Nanodisc	solutions	in	100	mM	KPi,	pH	7.4	buffer	containing	15%	ultrapure	glycerol	were	prepared	as	indicated	in	Chapter	2.2.3	and	Chapter	2.3.	
6.2.2	Preparation	of	Samples	for	rR	Spectroscopy	Samples	for	rR	spectroscopy	contained	100	µM	CYP17A1:Nanodiscs,	100	mM	KPi,	pH	7.4,	0.25	M	NaCl,	and	400	µM	of	progesterone	or	17a-hydroxyprogesterone,	pregnenolone,	or		
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17a-hydroxypregnenolone	(Sigma)	added	from	~8mM	methanolic	stocks.		Solutions	were	prepared	in	either	double	distilled	30%	(v/v)	glycerol	in	H2O	or	30%	(v/v)	glycerol-d3	in	D2O,	and	were	de-aerated	under	argon	for	5	minutes.	Samples	were	transferred	to	5	mm	NMR	tubes	(WG-5	Economy,	Wilmad)	and	reduced	under	anaerobic	conditions	with	a	1.5	fold	molar	 excess	 of	 sodium	 dithionite	 in	 the	 presence	 of	 2.5	µM	methyl-viologen.	 Each	sample	reduced	for	10	minutes	at	room	temperature.		Complete	reduction	was	verified	by	UV-Vis	 spectroscopy.	 	 NMR	 tubes	 were	 then	 sealed	 and	 transferred	 under	 anaerobic	conditions	 to	a	dry	 ice-ethanol	bath	held	at	 -15	 °C	where	 they	 cooled	 for	1	minute.	Oxy-ferrous	complexes	were	formed	by	bubbling	16O2	or	18O2	for	5	seconds,	followed	by	rapid	freezing	in	liquid	N2.		Samples	were	stored	at	77K	until	analysis.				
6.2.3	rR	Measurements	The	resonance	Raman	spectra	of	oxy	complexes	of	Nanodisc-incorporated	CYP17A1	were	acquired	 using	 a	 Spex	 1269	 spectrometer	 equipped	 with	 a	 Spec-10	 LN-cooled	 detector	having	2048	pixels	 (Princeton	 Instruments,	NJ).	The	data	were	measured	with	413.1	nm	excitation	 line	 from	 a	Kr+	 laser	 (Coherent	 Innova	 Sabre	 Ion	 Laser)	 The	 rR	 spectra	were	collected	 using	 back	 scattering	 (180°)	 geometry	with	 the	 laser	 beam	being	 focused	 by	 a	cylindrical	lens	to	form	a	line	image	on	the	sample.	The	laser	power	was	adjusted	to	1	mW	or	less.	All	measurements	were	performed	at	77	K	and	total	collection	time	was	4-5	hrs	in	the	high	frequency	region	and	6-7	hrs	in	the	low	frequency	region.	The	slit	width	was	set	at	150	µm	and	 the	1200	g/mm	grating	were	used;	 the	 linear	 reciprocal	dispersion	 is	0.655	nm/mm	 near	 400nm,	 corresponding	 to	 0.46	 cm-1/pixel.	 The	 spectral	 resolution	 was	determined	 to	be	4.1	cm-1.	The	 frozen	samples	were	contained	 in	5	mm	O.D.	NMR	tubes	(WG-5	ECONOMY,	Wilmad).	The	NMR	tubes	were	positioned	into	a	double-walled	quartz	low	
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temperature	 cell	 filled	 with	 liquid	 nitrogen.	 The	 sample	 tubes	 were	 spun	 to	 avoid	 local	heating.	 Spectra	 were	 calibrated	 with	 fenchone	 (Sigma-Aldrich,	WI)	 and	 processed	with	Grams/32	AI	software	(Galactic	Industries,	Salem,	NH).		
6.3	Results	
	 Shown	in	Figure	6.1	are	the	rR	spectra	obtained	for	the	16O2	adduct	of	PROG	bound	CYP17A1.	In	addition	to	structure-sensitive	heme	modes,	 including	 	ν4,	ν3,	and	ν2,	 the	key	ν(16O-16O)	 mode	 is	 observed	 at	 1140	 cm-1	 as	 confirmed	 by	 the	 uncluttered	 16O2/18O2	difference	spectrum.	The	ν(Fe-O)	stretching	mode	appears	at	536	cm-1,	as	documented	in	the	
16O2/18O2	difference	trace	(Figure	6.1,	panel	A).		These	frequencies	for	the	Fe-O-O	fragment	are	similar	to	those	observed	for	other	P450s	wherein	this	fragment	is	weakly	H-bonded	to	active	site	protein	side	chains.	Significantly,	 spectra	acquired	 for	 this	 sample	 in	solutions	prepared	 in	D2O	(left	and	right	 traces	 in	 lower	section	of	Figure	6.1,	panel	A)	showed	no	difference	for	this	non-H-bonding	substrate.			 Shown	in	Figure	6.1,	panel	B,	top	trace,	is	the	rR	spectrum	obtained	for	the	16O2	adduct	of	CYP17A1	harboring	17-OH	PROG	at	its	active	site.		The	ν(16O-16O)	mode	now	appears	~9	cm-1	 lower	 at	 1131	 cm-1.	 Expansion	 of	 this	 spectral	 region,	 and	 comparison	 with	 the	spectrum	acquired	with	18O2,	shows	that	the	Fe-O-O	fragment	exists	in	two	conformations.	The	minor	conformer	is	apparently	identical	to	the	form	observed	when	PROG	is	bound.	As	is	evidenced	by	a	telltale	2	cm-1	shift	to	higher	frequency	in	solutions	prepared	in	D2O114,	the	dominant	form,	occurring	at	1131	cm-1,	is	H-bonded.		It	is	most	reasonable	to	attribute	the	clearly	 observed	H-bonding	 interaction	 to	 the	 newly	 introduced	 C17-OH(D)	 functionality.		
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Note	that	this	lowering	of	the	ν(O-O)	mode	is	correlated	with	a	corresponding	6	cm-1	increase	in	the	frequency	of	the	ν(Fe-O)	band	relative	to	its	value	in	the	PROG-bound	enzyme.		 Corresponding	spectral	data	for	the	PREG	and	17-17-OH	PREG-bound	enzymes	are	shown	in	Figure	6.2.	As	in	the	case	of	the	PROG-bound	enzyme,	the	ν(O-O)	and	ν(Fe-O)	modes	of	the	PREG-bound	enzyme	are	observed	near	1140	and	535	cm-1	and	show	no	evidence	for	H-bonding.	As	shown	in	Figure	6.2,	panel	B,	for	the	17-OH	PREG	sample,	the	ν(O-O)	mode	is	shifted	down	by	only	5	cm-1	compared	with	its	value	for	the	PREG-bound	form	and	exhibits	a	barely	detectable	upshift	in	deuterated	solvents.	However,	the	ν(Fe-O)	is	observed	at	526	cm-1,	exhibiting	a	9	cm-1	shift	to	lower	frequency	compared	to	the	value	observed	for	the		Fe-O-O	fragment	present	in	the	sample	containing		non-H-bonding	PREG.	The	key	finding	in	this	case	 is	 the	rather	dramatic	differences	are	observed	when	comparing	the	samples	bound	with	 17-OH	 PROG	 and	 17-OH	 PREG.	 	 Though	 introduction	 of	 the	 17-OH	 group	 causes	downshifts	of	the	ν(O-O)	modes	for	both	17-OH	PROG	and	17-OH	PREG,	the	corresponding	ν(Fe-O)	modes	shift	in	opposite	directions:	the	17-OH	PROG	yields	a	6	cm-1	upshift	for	this	mode	while	 the	 17-OH	PREG	 shows	 a	 9	 cm-1	downshift.	 It	 is	 emphasized	 that	 rR	 spectra	acquired	with	356	nm	excitation	for	all	four	samples	showed	no	evidence	for	changes	in	the	trans	Fe-S	bond	strength,	 indicating	 that	 the	effects	on	 the	Fe-O-O	 fragment	arise	mainly	from	 distal	 side	 interactions,	 and	 consistent	 with	 results	 obtained	 in	 the	 ferric	 and	ferrous:CO	states	in	the	previous	chapter.		
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6.4	Conclusions	
While	the	acquisition	of	reference	data	for	the	vibrational	modes	of	dioxygen	adducts	of	heme	 proteins	 has	 been	 hampered	 by	 their	 relative	 instability	 towards	 auto-oxidation,	certain	fundamental	patterns	have	emerged.97,114–117	Studies	of	globin	mutants	lead	to	the	conclusion	that	H-bonds	to	the	inner	(proximal)	O	of	the	Fe-O-O	fragment	cause	a	decrease	in	the	ν(Fe-O)	mode,	with	similar	but	smaller	effects	on	the	ν(O-O)--a	positive	correlation.118	On	the	other	hand,	H-bonding	to	the	outer	(terminal)	O	often	leads	to	significant	lowering	of	the	 ν(O-O)	 fragment	 in	 P450s	 and	 related	 enzymes.114–117	 	 Importantly,	 recent	 DFT	calculations	 on	 histidine-ligated	 oxy	 complexes	 indicate	 that,	 other	 factors	 being	 held	constant,	H-bond	donation	to	the	proximal	oxygen	atom	(OP)	causes	both	the	ν(Fe-O)	and	the	ν(O-O)	modes	 to	shift	 in	concert	 to	 lower	 frequency,	as	a	result	of	weakening	of	both	bonds	by	withdrawing	of	electrons	into	the	non-bonding	sp2	orbital	on	the	OP.97	In	contrast,	H-bond	donation	to	the	terminal	oxygen,	OT,	results	in	a	straightforward	increase	in	back-bonding	resulting	in	a	negative	correlation,	wherein	the	ν(O-O)	decreases	while	the	ν(Fe-O)	shows	 a	 corresponding	 increase	 in	 frequency.	 Therefore,	 collectively,	 the	 rR	 spectra	presented	 in	 Figures	 6.1	 and	6.2	 provide	 convincing	 evidence	 that	 the	 two	hydroxylated	substrates	interact	at	opposite	ends	of	the	Fe-O-O	fragment,	as	depicted	in	Figure	6.3,	leading	to	crucial	implications	for	CYP17A1	function.		It	is	anticipated	that	these	interactions	dictate	the	preference	for	the	hydroxylation	and	lyase	pathways.	Such	H-bonding	interactions	with	OT	 are	 expected	 to	 promote	 O-O	 bond	 cleavage	 and	 CpdI	 formation,	whereas	 the	 H---OP	interaction	could	prolong	the	lifetime	of	the	ferric	peroxo-	intermediate	that	is	suggested	to	be	the	active	fragment	in	the	lyase	reaction.	Alternatively,	proximal	hydrogen	bonding	could	promote	lyase	chemistry	by	liberating	the	distal	oxygen	to	initiate	a	nucleophilic	attack	on	
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the	C20	carbonyl.		Indeed,	similar	differences	in	OT	vs	OP	H-bonding	interactions	have	been	invoked	 to	 explain	differences	 in	 the	nitric	 oxide	 synthase	 reaction;	 in	 the	 first	 cycle	 the	arginine	substrate	is	suggested	to	provide	a	H---OT	interaction	and	facilitate	CpdI	formation,	whereas	in	the	second	cycle	the	hydroxylated	substrate	(NOHA)	is	believed	to	provide	a	H---OP	interaction	and	proceed	through	a	peroxo-	intermediate.117,119,120		In	 summary,	 this	 chapter	 reports	 use	 of	 Nanodisc	 incorporated	 human	 CYP17A1	 to	facilitate	collection	of	high	resolution	rR	spectra	in	order	to	define	the	active	site	hydrogen	bonding,	where	the	only	significant	change	being	compared	is	a	difference	between	a	3β-OH	group	vs	a	corresponding	ketone	 in	natural	CYP17A1	substrates.	Significantly,	 this	 single	difference	 at	 a	 relatively	 remote	 site	 is	 nevertheless	 sufficient	 to	 alter	 the	 H-bonding	interactions	with	the	critical	Fe-O-O	fragment	in	such	a	way	as	to	dictate	its	predisposition	towards	one	of	two	alternative	reaction	pathways.	 	This	conclusion	has	a	structural	basis:	crystal	structures	with	abiraterone	acetate	bound	have	shown	that	the	OH-	group	on	C3	of	its	pregnene	nucleus		forms	a	H-bond	to	the	ketone	on	the	side	chain	of	Asn	202	that	projects	into	the	active	site	cavity.		An	additional	H-bonding	interaction	with	the	amino	group	of	this	residue	is	noted	with	Glu	305	that	presumably	stabilizes	this	particular	rotomer.		Should	this	structure	reflect	a	persistent	state,	 it	would	be	expected	that	substrate	molecules	with	H-bond	donor	at	the	C3	position	(PREG/17-OH	PREG)	would	bind	the	enzyme	in	a	state	more	favorable	to	lyase	catalysis.				 	
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6.5	Tables	and	Figures	
										
Figure	6.1:	rR	Spectra	of	PROG	and	17-OH	PROG	CYP17A1	Oxy-Complex	The	rR	spectra	of	PROG	(A)	and	17-OH	PROG	(B)	bound	16O2	adducts	(top).		The	bottom	section	of	each	panel	shows	16O2-18O2	difference	plots	in	H2O	(upper)	and	D2O	(lower)	buffers.			 	
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Figure	6.2:	rR	Spectra	of	PREG	and	17-OH	PREG	CYP17A1	Oxy-Complex	The	rR	spectra	of	PREG	and	17-OH	PREG	bound	16O2	adducts	of	CYP17A1	Nanodiscs	in	H2O	buffer	(panel	A	and	B,	respectively).		The	lower	section	of	each	panel	shows	16O2	–	18O2	difference	plots	in	H2O	(upper)	and	D2O	(lower)	buffers.			 	
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Figure	6.3:	Proposed	Model	of	Interaction	with	the	Oxy-Complex	The	human	CYP17A1	protein-substrate	interaction	derived	from	these	data,	wherein	Asn	202	and	the	C3	substituent	dictate	H-bonding	to	either	the	proximal	or	distal	oxygen.				 	
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Chapter	7:	Characterizing	the	Active	Intermediate	
in	Androgen	Formation5	
7.1	Introduction	
		 Building	on	work	detailed	in	the	previous	chapters,	it	is	clear	that	investigation	of	the	peroxo-	 states	 of	 CYP17A1	 is	 crucial	 in	 defining	 the	 nature	 of	 the	 reactive	 intermediate	responsible	 for	 carbon-carbon	 bond	 scission.	 	 This	 key	 branching	 point	 in	 human	steroidogenesis	 has	 been	 at	 the	 center	 of	 a	 protracted	 debate	 regarding	 whether	 the	traditional	CpdI,	or	a	peroxoanion	is	responsible	for	cleavage	of	the	17,20	bond,	a	reaction	that	is	the	first	committed	step	in	androgen	formation.		Early	work	by	the	Akhtar	group	first	suggested	that	this	reaction	could	be	initiated	by	a	nucleophilic	attack	on	the	C20	carbonyl	yielding	a	peroxo-hemiacetal	that	could	decay	to	androgen	product	and	acetic	acid	via	either	homolytic	 or	 heterolytic	 scission	 of	 the	 dioxygen	 bond	 therein.50	 	 However,	 alternate	suggestions	of	radical	mechanisms	involving	CpdI	have	also	been	proposed.53,121,122		Though	strong	support	is	given	to	the	preceding	hypothesis	by	the	work	documented	earlier	in	this	dissertation,	 characterization	 of	 an	 iron-ligated	 peroxo-hemiacetal	 would	 obviously	represent	a	significant	movement	towards	concluding	this	decades	long	debate.				 Previously,	the	highly	unstable	intermediate	species	occurring	after	reduction	of	the	oxy-complex	have	proved	recalcitrant	to	laboratory	analysis	due	to	the	inability	to	generate	
																																																								
5	Portions	of	this	chapter	were	reprinted	with	permission	from	Mak,	P.	J.,	Gregory,	M.	C.,	Denisov,	I.	G.,	Sligar,	S.	G.	&	Kincaid,	J.	R.	Unveiling	the	crucial	intermediates	in	androgen	production.	Proc.	Natl.	Acad.	Sci.	112,	15856–15861	(2015).		
	 82	
sufficiently	large	populations	to	observe	experimentally.		However,	in	recent	years	barriers	to	 interrogating	 these	species	have	been	overcome:	 the	peroxoanion,	hydroperoxo-ferric,	and	 CpdI	 intermediates	 have	 all	 been	 isolated	 and	 characterized	 in	 various	 P450	enzymes.114,123	 	 To	 a	 large	 extent,	 these	 advances	 have	 been	 made	 through	 use	 of	cryoradiolytic	reduction	of	oxy-ferrous	P450	enzymes.		In	such	a	method,	the	oxy-complex	is	formed	in	a	solution	containing	a	significant	percent	of	glycerol	and	subsequently	trapped	by	immersion	in	liquid	N2.		Electron	input	needed	to	form	the	peroxoanion	is	provided	via	radiolysis,	 typically	 gamma-rays	 from	 a	 60Co	 source,	 at	 cryogenic	 temperatures.	 	 At	 77K,	irradiation	results	in	formation	of	various	radiolytic	products	that	are	trapped	in	the	frozen	solvent	 matrix,	 and	 electrons	 which	 are	 free	 to	 reduce	 the	 oxy-complex	 and	 form	 the	peroxoanion.124–126				 This	method	was	utilized	to	trap	the	peroxoanion	using	CYP17A1	Nanodiscs	in	the	presence	of	saturating	concentrations	of	the	preferred	substrates,	PREG	and	17-OH	PREG.		Both	optical	and	resonance	raman	samples	were	measured	at	various	temperatures	as	the	resultant	peroxoanion	was	permitted	to	thermally	anneal.				 	
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7.2	Materials	and	Methods	
7.2.1	Protein	Expression,	Purification	and	Nanodisc	Incorporation	of	CYP17A1.	CYP17A1	Nanodisc	solutions	in	100	mM	KPi,	pH	7.4	buffer	containing	15%	ultrapure	glycerol	were	prepared	as	indicated	in	Chapter	2.2.3	and	Chapter	2.3.	
7.2.2	Preparation	of	Samples	for	Raman	Spectroscopy	The	rR	samples	contained	280	μM	ND/CYP17A1	in	100	mM	potassium	phosphate	(pH	7.4),	250	mM	sodium	chloride,	 30%	 (vol/vol)	distilled	 glycerol,	 6.24	μM	methyl	 viologen,	 and	either	 450	 μM	 PREG	 or	 400	 μM	 17-OH	 PREG.	 Deuterated	 samples	 were	 prepared	 by	exhaustive	exchange	into	identical	buffer	adjusted	to	pD	7.4	[electrode	calibrated	by	method	of	Glasoe	and	Long85]	prepared	with	100%	D2O	and	distilled	glycerol-d3.	Ferric	samples	were	then	contained	in	5-mm-OD	NMR	tubes	(WG-5	ECONOMY;	Wilmad)	and	de-aerated	under	argon	 for	5	min,	 followed	by	reduction	under	anaerobic	conditions	with	a	1.5-fold	molar	excess	of	sodium	dithionite.	Each	sample	was	then	transferred	to	a	dry	ice-ethanol	bath	held	at	−15	°C,	where	it	was	cooled	for	1	min.	Oxy-ferrous	complexes	were	formed	by	addition	of	
16O2,	 18O2,	 or	 16O18O	 scrambled	 oxygen)	 for	 10	 s,	 followed	by	 rapid	 freezing	 in	 liquid	N2.	Frozen	samples	containing	oxy-ferrous	CYP17A1	were	subsequently	radiolytically	reduced	to	the	peroxo-state	by	a	4-Mrad	dose	of	gamma-rays	in	a	Gammacell	200	Excel	60Co	source	while	immersed	in	liquid	nitrogen	as	described	previously	
7.2.3	rR	Measurements	Samples	of	irradiated	oxy-ND/CYP17A1	were	excited	using	a	441.6-nm	line	provided	by	a	He-Cd	laser	(IK	Series	He-Cd	laser;	Kimmon	Koha	Co.),	whereas	the	samples	annealed	to	 190	 K	 were	 measured	 with	 406.7-	 and	 413.1-nm	 excitation	 lines	 from	 a	 Kr+	 laser	
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(Coherent	 Innova	Sabre	 Ion	Laser).	The	rR	spectra	of	all	 samples	were	measured	using	a	Spex	 1269	 spectrometer	 equipped	 with	 Spec-10	 LN-cooled	 detector	 (Princeton	Instruments).	The	slit	width	was	set	at	150	μm,	and	the	1,200-g/mm	grating	was	used;	with	this	grating,	 the	resultant	spectral	dispersion	 is	0.46	cm−1	per	pixel.	The	 laser	power	was	kept	 at	 ∼1	mW	 or	 less	 to	minimize	 photodissociation.	Moreover,	 to	 avoid	 laser-induced	heating	and	protein	degradation,	the	samples	were	contained	in	spinning	NMR	tubes	(5-mm	outside	diameter,	WG-5	ECONOMY;	Wilmad).	The	180°	backscattering	geometry	was	used	for	all	measurements,	and	the	laser	beam	was	focused	onto	the	sample	using	a	cylindrical	lens.	The	NMR	tubes	were	positioned	into	a	double-walled	quartz	low-temperature	cell	filled	with	 liquid	nitrogen.	All	measurements	were	done	at	77	K,	 and	 total	 collection	 time	was	around	6	h	for	the	irradiated	samples	and	∼8–9	h	for	the	annealed	samples.	Spectra	were	calibrated	 with	 fenchone	 (Sigma–Aldrich)	 and	 processed	 with	 GRAMS/32	 AI	 software	(Galactic	Industries).	
7.2.4	Preparation	of	Optical	Samples	and	Collection	of	Optical	Spectra	CYP17A1	 Nanodiscs	 in	 100	 mM	 potassium	 phosphate	 (pH	 7.4),	 15%	 (vol/vol)	glycerol,	and	400	μM	PREG	or	17-OH	PREG	were	anaerobically	reduced	with	a	1.5-fold	molar	excess	of	sodium	dithionite	with	the	aid	of	methyl	viologen	at	a	1:40	ratio	of	redox	mediator	to	P450.	Oxy-ferrous	CYP17A1	was	formed	by	rapid	injection	of	this	solution	into	100	mM	potassium	phosphate	 (pH	 7.4)	 buffer	 containing	 67.5%	 (vol/vol)	 glycerol	 contained	 in	 a	methacrylate	cuvette	and	chilled	 to	243	K.	After	25	s	of	vigorous	mixing,	 the	sample	was	rapidly	cooled	to	210	K,	and	then	to	77	K	at	a	rate	of	∼4	K⋅min−1.	The	final	concentration	of	ND/CYP17A1	 and	 glycerol	 was	 ∼30	 μM	 and	 60%	 (vol/vol),	 respectively.	 Samples	 were	irradiated	as	described	in	section	7.2.2	and	then	photobleached	for	30	min	under	a	100-W	
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tungsten-halogen	lamp	behind	a	450-nm	long-pass	filter	while	immersed	in	liquid	nitrogen.	Spectra	were	collected	in	a	home-built	optical	cryostat127	aligned	within	the	beam	path	of	a	Cary	 300	 spectrophotometer	 as	 the	 temperature	 was	 increased	 linearly	 at	 a	 rate	 of	 ∼1	K⋅min−1.		
7.3	Results	
7.3.1	Thermal	Annealing	of	Optical	Peroxo-	Samples		 Utilizing	a	home-built	optical	cryostat,	samples	were	annealed	from	77K	to	190K	at	a	roughly	 linear	 rate	of	~1	K	per	minute.	 	This	 ramp	rate	permits	 collection	of	a	 complete	spectrum	from	350	–	500	nm	at	1	K	intervals.		A	strong	negative	absorption	band	near	440	nm	appeared	 in	 the	difference	 spectrum	of	 both	PREG	and	17-OH	PREG,	 consistent	with	formation	 and	disappearance	 of	 the	 peroxo-ferric	 intermediate	 throughout	 the	 course	 of	annealing.	 	 In	the	case	of	the	PREG	sample,	a	steady	loss	of	the	peroxo-	intermediate	was	accompanied	by	an	associated	increase	in	absorption	at	417	nm,	consistent	with	a	transition	to	the	low	spin	ferric	state.		Such	a	transition	would	be	expected	should	a	CpdI	mechanism	operate	in	this	hydroxylation,	as	the	transition	to	the	hydroperoxo-ferric	state	is	not	optically	distinguishable	 from	 the	 peroxoanion128	 and	 the	 rapid	 formation	 and	 decay	 of	 CpdI	 is	unlikely	to	be	observed.		Unexpectedly,	in	an	identical	experiment	conducted	in	the	presence	of	17-OH	PREG	decay	of	the	peroxo-like	Soret	at	437	nm	gave	rise	to	an	unidentified	species	with	a	Soret	at	405	nm	(Figure	7.1).	
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7.3.2	rR	Spectra	of	the	Irradiated	Oxy	Complexes		 Next,	 rR	spectroscopy	was	used	to	 identify	 the	key	ν(O-O)	and	ν(Fe-O)	vibrational	modes	 of	 interest.	 	 Figure	 7.2,	 panel	 A	 shows	 spectra	 obtained	 at	 77K	 for	 the	 sample	containing	the	PREG	substrate.		Two	sets	of	oxygen	isotope-sensitive	(16O2/18O2)	modes	are	clearly	seen	in	the	16O-18O	difference	traces	of	the	initial	cryoreduced	samples,	signaling	the	presence	of	two	intermediates.		One	species	exhibited	a	ν(16O-16O)	mode	at	802	cm−1,	with	its	corresponding	ν(18O-18O)	at	764	cm−1	(Δ16/18	=	38	cm−1),	and	a	ν(Fe-16O)	at	554	cm−1,	with	its	ν(Fe-18O)	mode	appearing	at	527	cm−1	(Δ16/18	=	27	cm−1).		No	observable	shift	in	the	difference	trace	generated	for	the	samples	prepared	in	D2O	was	evident	(bottom	trace	in	Figure	7.2).	The	lack	of	an	observable	hydrogen/deuterium	(H/D)	shift	is	entirely	consistent	with	assignment	of	this	set	of	bands	to	a	trapped	ferric	peroxo-intermediate	of	CYP17A1.		 The	second	species	in	this	sample	exhibits	a	ν(16O-16O)	mode	at	775	cm−1,	which	shifts	to	738	cm−1	for	the	18O-analog	(Δ16/18	=	37	cm−1),	and	a	corresponding	ν(Fe-16O)	at	572	cm−1,	shifting	to	545	cm−1	for	18O2	(Δ16/18	=	27	cm−1).		These	observed	16O-18O	isotope	shifts	are	 consistent	 with	 the	 isotope	 shifts	 predicted	 for	 Fe-O-O	 or	 Fe-O-O-H	 fragments.	Furthermore,	the	spectra	of	samples	acquired	in	buffers	prepared	with	D2O	reveal	that	the	775/572	cm−1	modes	shift	significantly,	confirming	the	identification	of	this	species	as	the	hydroperoxo-derivative.		Thus	even	at	77K	a	significant	fraction	of	the	peroxo-intermediate	was	 converted	 to	 the	 hydroperoxo-intermediate.	 This	 finding	 is	 particularly	 important,	revealing	 the	 fact	 that	 when	 PREG	 is	 bound	 to	 CYP17A1,	 the	 active	 site	 architecture	 is	arranged	to	promote	efficient	proton	transfer	thereby	facilitating	formation	of	CpdI	and	the	classical	hydroxylation	reaction	required	to	produce	17-OH	PREG.	
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	 In	the	case	of	the	lyase	substrate	17-OH	PREG,	which	projects	an	alcohol	into	the	heme	environment	that	forms	an	H-bond	with	the	proximal	oxygen	in	the	preceding	oxy-complex,	the	initial	product	of	cryoradiolysis	at	77	K	exhibits	a	ν(16O-16O)	mode	at	796	cm−1	(Δ16/18	=	38	cm−1),	and	a	corresponding	ν(Fe-16O)	mode	occurring	at	546	cm−1	(Δ16/18	=	24	cm−1).	Furthermore,	 the	 observed	 modes	 are	 insensitive	 to	 the	 H/D	 exchange,	 confirming	 the	identity	 of	 this	 species	 as	 a	 ferric	 peroxo-intermediate,	 but	 with	 a	 slightly	 different	disposition	 than	 seen	 for	 the	 PREG-bound	 sample.	 In	 fact,	 as	 described	 in	 the	 previous	chapter,	the	lowered	ν(Fe-16O)	frequency	of	the	peroxo-form	of	the	17-OH	PREG	sample	(546	cm−1),	relative	to	the	peroxo-form	of	the	PREG-bound	sample	(554	cm−1),	suggests	that	an	H-bonding	interaction	occurs	between	the	hydroxyl	group	of	the	substrate	and	the	proximal	oxygen	atom	of	the	Fe-Op-Ot	peroxo-fragment.				 Next,	 the	 samples	 were	 subjected	 to	 stepwise	 thermal	 annealing:	 samples	 were	immersed	in	a	pentane	bath	cooled	to	165	K	where	they	incubated	for	one	minute	before	being	returned	to	77	K.		Subsequent	rR	analysis	using	442-nm	excitation	(Figure	7.2,	panel	B)	 show	 that	 annealing	 of	 the	 PREG-bound	 sample	 resulted	 in	 clean	 conversion	 of	 the	peroxo-intermediate	 to	 more	 of	 the	 hydroperoxo-intermediate	 involved	 in	 the	hydroxylation	 pathway,	 with	 the	 extent	 of	 conversion	 estimated	 to	 be	 a	 factor	 of	approximately	 twofold.	 Interestingly,	similar	annealing	studies	of	 the	17-OH	PREG-bound	sample	provided	no	evidence	for	the	appearance	of	any	new	16O/18O-sensitive	bands	(Figure	7.2,	 panel	D).	 This	 outcome	was	not	 surprising,	 given	 that	 that	 the	newly	 arising	 second	intermediate	 has	 its	 Soret	maximum	near	 405	 nm,	 far	 from	 resonance	with	 the	 442-nm	excitation	line.		
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Indeed,	rR	spectral	measurements	on	annealed	samples,	using	the	406-nm	excitation	line	from	an	available	Krypton	ion	laser	(Figure	7.3),	yielded	a	new	set	of	strongly	enhanced	bands	 appearing	 at	 791	 cm−1	 (16O2	 sample)	 and	 749	 cm−1	 (18O2	 sample).	 The	 lack	 of	 an	observable	shift	 for	samples	prepared	 in	D2O-based	buffer	confirms	this	species	does	not	possess	a	bound	hydroperoxo-fragment.		This	rR	spectral	result	is	entirely	consistent	with	the	increase	of	the	405-nm	electronic	absorption	band	over	the	same	temperature	excursion.		It	is	noted	that	a	control	experiment	conducted	on	the	PREG-bound	sample	annealed	to	190	K,	using	the	same	406-nm	excitation	line,	did	not	show	any	evidence	for	a	feature	appearing	near	790	cm−1,	indicating	that	the	peroxo-hemiacetal	intermediate	is	encountered	only	with	the	17-OH	PREG	substrate,	but	not	with	the	PREG	substrate.			
7.4	Conclusions	
	 Although	the	observation	of	this	feature	appearing	at	791	cm−1	is	obviously	consistent	with	 an	 intermediate	with	 “peroxo-like”	 character,	 it	must	 be	 noted	 that	 this	 vibrational	frequency	and	16O/18O	isotopic	shifts	are	close	to	what	is	expected	for	the	ν(Fe	=	O)	mode	of	a	ferryl	heme	species.		The	frequencies	of	such	ferryl	species	depend	on	the	transaxial	ligand	and	distal	pocket	interactions,	with	reported	values	ranging	from	745	cm−1	up	to	about	800	cm−1	 129,130.	However,	 the	 assignment	 of	 this	 feature	 to	 a	 ferryl	 species	was	 ruled	 out	 by	experiments	conducted	with	scrambled	oxygen,	a	 (1:2:1)	mixture	of	 16O2/16O18O/18O2.	As	seen	 in	 Figure	 7.3,	 Inset,	 a	 distinctive	 difference	 pattern	 emerges	 when	 subtracting	 the	spectrum	 of	 the	 16O2	 sample	 from	 the	 spectrum	 of	 a	 sample	 prepared	 with	 scrambled	dioxygen.	If	the	791	cm−1/749	cm−1	pair	arises	from	a	ferryl	species	(generated	through	O-O	
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bond	 cleavage),	 a	 clean	 two-component	 difference	 pattern	 (Fe-16O	 and	 Fe-18O)	would	 be	observed	in	the	trace	shown.	However,	we	clearly	see	a	third	band	at	770	cm−1,	confirming	the	fact	that	the	observed	intermediate	contains	an	intact	O-O	bond	(i.e.,	16O-18O),	consistent	with	the	proposed	peroxo-hemiacetal	species.	Finally,	it	is	also	noted	that	the	corresponding	iron-oxygen	ν(Fe-O)	modes,	 expected	 to	be	 seen	 for	 such	a	peroxo-like	 intermediate,	 are	indeed	seen	as	weak	features	appearing	at	580	cm−1	(16O2)	and	553	cm−1	(18O2).	Collectively,	these	spectroscopic	data	establish	the	nature	of	the	intermediate	as	the	peroxo-hemiacetal.		 Further	support	for	this	structural	interpretation	of	the	species	trapped	at	190	K	is	provided	from	previous	studies	of	other	iron-oxygen	systems,	whose	structures	are	closely	related	to	this	intermediate	(e.g.,	acylperoxo-adducts	of	heme-	and	nonheme	proteins	that	possess	an	Fe-O-O	peroxo-fragment	 linked	 to	an	oxidized	 carbon).	Unlike	 the	 red-shifted	Soret	 band	 at	 435–440	 nm	 characteristic	 for	 hydroperoxo-ferric	 intermediates	 in	 P450	enzymes114,128,	a	blue-shifted	Soret	maximum	at	405	nm	is	consistent	with	the	bands	seen	for	an	acylperoxo-species	derived	from	metachloroperoxybenzoic	acid	(mCPBA)131,	as	well	as	other	substituted	peroxybenzoic	acids.	In	all	cases,	the	Soret	maximum	varies	from	413	nm	for	the	mCPBA	adduct	down	to	409	nm	with	electron-donating	groups,	such	as	the	p-methoxy	analog.	Thus,	the	405-nm	maximum	for	the	peroxo-hemiacetal	intermediate,	with	its	 relatively	 less	electrophilic	 carbon	atom	compared	with	 the	acylperoxo-species,	 is	not	unexpected.	A	more	convincing	argument	for	the	validity	of	the	assigned	structure	can	be	made	 by	 noting	 that	 Que	 and	 coworkers132	 have	 recently	 isolated	 and	 spectroscopically	characterized	an	acylperoxo-derivative	of	a	nonheme	iron	protein,	reporting	a	value	of	792	cm−1	for	the	frequency	of	the	ν(O-O)	mode,	a	virtually	identical	value	(791	cm−1)	to	the	value	we	observe	for	the	assigned	peroxo-hemiacetal	intermediate.		
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	 The	results	presented	here,	obtained	through	the	combined	application	of	Nanodisc	technology,	cryoreduction,	and	rR	and	optical	spectroscopies,	reveal	that	owing	to	the	highly	directional	 H-bonding	 interaction	 between	 the	 hydroxyl	 group	 of	 17-OH	 PREG	 and	 the	proximal	oxygen	of	the	ferric	peroxo-anion,	this	intermediate	is	poised	for	attack	on	the	C20	carbon	atom	of	the	substrate.	Furthermore,	methodical	application	of	the	structure-sensitive	rR	technique,	using	judicious	isotopic	labeling	strategies,	provides	convincing	evidence	that	the	resulting	crucial	intermediate	of	this	lyase	reaction	is	indeed	the	previously	proposed	peroxo-hemiacetal	derivative.		Therefore,	a	new	view	P450	catalytic	cycle	has	emerged	when	CYP17A1	is	employed	in	C-C	bond	scission	(Figure	7.4).			
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7.5	Tables	and	Figures	
																
Figure	7.1:	Thermal	Annealing	of	Optical	Samples			Thermal	annealing	of	peroxo-ferric	intermediates	monitored	by	optical	absorption	spectroscopy	in	CYP17A1	with	PREG	(A)	and	17-OH	PREG	(B).			 	
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Figure	7.2:	rR	Spectral	Data	for	Irradiated	Dioxygen	Adducts	The	rR	16O2-18O2	difference	traces	in	H2O	and	D2O	buffers	of	irradiated	oxy-CYP17A1	samples	(before	annealing)	with	PREG	 (A)	 and	17-OH	PREG	 (B)	 and	 corresponding	 samples	 after	annealing	to	165	K	(C)	and	(D)	are	shown.		Excitation	was	at	442	nm.		 	
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Figure	7.3:	rR	Spectral	Data	Annealed	to	190K	(405nm	Excitation)	rR	spectral	data	for	irradiated	dioxygen	adducts	of	CYP17A1	samples	with	17-OH	PREG	annealed	at	190	K.	16O2/H2O	(A),	18O2/H2O	(B),	16O2/D2O	(C),	18O2/D2O	(D),	and	their	16O2-
18O2	difference	traces.	(D,	Inset)	Difference	trace	of	scrambled	oxygen	(SC)	and	the	16O2	spectrum.	Spectra	were	measured	with	a	406-nm	excitation	line	at	77	K,		
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Figure	7.4:	P450	Catalytic	Cycle	Operating	in	Androgen	Formation	Cytochrome	P450	enzymatic	cycle	and	formation	of	a	peroxo-hemiacetal	intermediate.	 	
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Chapter	8:	Conclusions	
	 CYP17A1	is	a	steroidogenic	enzyme	of	critical	importance,	occupying	the	“crossroad”	that	 exists	 at	 the	 center	 of	 the	 human	 steroidogenic	 pathway.	 	 While	 its	 17a-hydroxy	products	are	essential	 in	a	variety	of	biological	processes,	 the	 latter	17,20	carbon-carbon	bond	 scission	 catalyzed	 by	 this	 enzyme	 is	 particularly	 intriguing.	 Though	 subsequent	biological	transformations	are	required	to	generate	the	potent	androgen	receptor	agonists	testosterone	and	dihidrotestosterone,	the	upstream	lyase	activity	of	CYP17A1	is	rate	limiting	in	 their	 production.	 	 The	 importance	 of	 these	 androgens	 in	 the	 proliferation	 of	 prostate	cancer	coupled	with	disappointing	performance	of	5a-reductase	 inhibitors	and	androgen	receptor	 antagonists	 has	 driven	 an	 explosion	 of	 interest	 in	 this	 enzyme,	 most	 notably	resulting	in	the	development	and	approval	of	its	inhibitor	Abiraterone	acetate.		 Multiple	 laboratories	 publicly	 claim	 to	 be	 engaged	 in	 developing	 lyase-specific	 or	mechanism	based	inhibitors,	but	until	recently	the	catalytic	processes	driving	these	targeted	reactions	have	remained	veiled,	representing	a	significant	impediment	to	the	development	of	 next-generation	 CYP17A1	 inhibitors	 for	 the	 treatment	 of	 prostate	 cancer.	 	 Recent	advances	such	as	the	development	of	the	Nanodisc	system	and	cryoradiolytic	reduction	of	P450s	 have	 finally	 permitted	 removal	 of	 the	 shroud	 that	 obfuscated	 the	 identity	 and	properties	of	the	key	transient	intermediates	that	drive	lyase	catalysis.		This	dissertation	has	described	the	joint	effort	of	the	Sligar	and	Kincaid	laboratories	to	employ	these	emerging	technologies	to	define	the	structural	and	chemical	features	of	CYP17A1	and	its	substrates	that	drive	this	enzyme’s	chimeric	reactivity.	
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	 Beginning	with	a	synthetic	gene,	expression	and	purification	conditions	were	devised	that	were	 able	 to	 yield	~10	mg/L	 of	 highly	 purified,	 full-length	 CYP17A1	 in	 a	 detergent	solubilized	form.		Appropriate	parameters	for	the	incorporation	of	this	enzyme	into	~10	nm	Nanodiscs	 were	 identified	 and	 a	 protocol	 was	 developed	 that	 consistently	 produced	homogeneous	 CYP17A1:Nanodiscs	 in	 high	 yield.	 	 Using	 the	 resultant	 preparation,	 the	substrate	 binding	 properties	 of	 PREG,	 PROG,	 17-OH	 PREG,	 and	 17-OH	 PROG	 were	characterized	by	both	UV-Visible	and	resonance	Raman	spectroscopy.		Both	PREG	and	PROG	bound	tightly	with	<	100	nM	spectral	dissociation	constants	and	their	binding	resulted	in	complete	transition	to	the	high	spin	5	coordinate	state.		17-OH	PREG	and	17-OH	PROG	bind	the	enzyme	less	tightly,	with	~	1µM	Ks	values	and	result	in	only	a	60%	transition	to	the	HS	form,	 likely	 due	 to	 interaction	 of	 the	 17a-OH	 group	with	 the	 heme	 iron	 atom.	 	 Notably,	binding	 of	 these	 substrates	 does	 not	 have	 any	 significant	 impact	 on	 heme	 peripheral	substituents	or	the	u(Fe-S)	mode,	 indicating	that	 important	structural	elements	are	 likely	derived	from	interactions	between	the	substrate	and	bound	exogenous	ligands.		 Steady	state	turnover	experiments	were	conducted	in	the	absence	and	presence	of	cyt	b5,	and	confirmed	previous	 reports	of	 the	stimulatory	effect	of	 this	protein.	 	Turning	towards	identification	of	the	reactive	intermediate	responsible	for	lyase	catalysis,	the	T306A	mutant,	with	an	 impaired	proton	delivery	shuttle,	was	studied.	 	 	This	mutant	showed	the	expected	large	extent	of	uncoupling	when	catalyzing	hydroxylation	chemistry,	but	androgen	formation	from	both	17-OH	PREG	and	17-OH	PROG	was	largely	unimpaired,	suggesting	that	lyase	chemistry	may	operate	to	some	extent	without	the	involvement	of	protons.		Next,	KSIE	data	 was	 collected	 for	 the	 steady	 state	 turnover	 of	 both	 PREG	 and	 17-OH	 PREG.	 	 PREG	hydroxylation	exhibited	the	expected	kH/kD	of	1.3,	however	in	the	hase	of	DHEA	formation	a	
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large	(0.39)	inverse	isotope	effect	was	observed,	again	suggesting	involvement	of	a	ferric-peroxoanion.				 						In	 another	 experiment,	 the	 oxy-complex	 of	 CYP17A1	 was	 probed	 by	 rR	spectroscopy	in	the	presence	of	all	four	native	substrates.		Both	PREG	and	PROG	were	found	not	to	interact	with	the	iron-ligated	dioxygen	adduct,	an	unsurprising	result	given	the	lack	of	perturbation	noted	of	the	ferrous-CO	complex	in	previous	studies.		On	the	contrary,	17-OH	 PREG	 and	 17-OH	 PROG	were	 found	 to	 form	 hydrogen	 bonds	 with	 the	 oxy	 complex.		Surprisingly,	while	17-OH	PROG	was	found	to	form	a	H-bond	with	the	terminal	oxygen,	the	preferred	substrate	for	lyase	catalysis,	17-OH	PREG,	was	found	to	form	an	H-bond	with	the	proximal	 oxygen	 in	 this	 intermediate	 state.	 	 Owing	 to	 the	 roughly	 50-fold	 preference	 of	CYP17A1	for	this	substrate,	this	result	suggests	that	the	directionality	of	this	H-bond	may	be	an	 important	 factor	 in	 driving	 peroxoanion	 mediated	 androgen	 formation	 by	 properly	orienting	the	substrate	C20	carbonyl	for	a	nucleophilic	attack.		 Finally,	 the	 oxy	 form	 of	 CYP17A1	 in	 the	 presence	 of	 PREG	 and	 17-OH	 PREG	was	cryoreduced	 to	 form	 the	 peroxo	 species.	 	 In	 the	 case	 of	 PREG,	 even	 at	 77K	 a	 significant	fraction	 of	 the	 ferric-peroxoanion	 had	 already	 transitioned	 to	 the	 hydroperoxo-	 state.		Conversely,	even	after	annealing	to	165K	the	17-OH	PREG	sample	still	contained	only	the	ferric-peroxoanion.	 	 Excitation	with	 a	 405	 nm	 laser	 line	 after	 further	 annealing	 to	 190K	permitted	 observation	 of	 a	 previously	 unknown,	 H/D	 insensitive,	 mode	 at	 791	 cm-1	consistent	with	a	bound	peroxo-hemiacetal.					 CpdI	mediated	 C-C	 bond	 scission	 is	 wholly	 incompatible	 with	 the	 presence	 of	 an	inverse	KSIE,	the	appearance	of	a	peroxo-hemiacetal,	and	normal	catalysis	by	and	enzyme	with	an	impaired	proton	shuttle.	 	Thus,	 these	results,	 taken	as	a	whole,	clearly	define	the	
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peroxoanion	 as	 the	 reactive	 intermediate	 in	 androgen	 formation	when	 17-OH	PREG	 is	 a	substrate.	 Furthermore,	 these	 findings	 highlight	 the	 potential	 for	 innovation	 when	collaborative	endeavors	integrate	biology,	biochemistry,	biophysics,	and	nanotechnology.						 	
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Appendix	
DNA	sequence	of	CYP17A1	Gene	ATGGCTCTGTTATTAGCAGTTTTCCTGCTGACCTTGGCATACCTGTTCTGGCCGAAACGTCGTTGTCCAGGTGCTAA
GTATCCGAAAAGCCTGCTGAGCTTGCCGCTGGTGGGTAGCTTGCCTTTTCTGCCGCGTCACGGTCACATGCACAACA
ACTTTTTCAAGCTGCAGAAGAAATACGGCCCGATCTATTCCGTGCGTATGGGCACCAAAACCACCGTTATCGTTGGC
CACCATCAACTGGCTAAAGAGGTTCTGATTAAGAAAGGTAAGGACTTCAGCGGTCGTCCGCAAATGGCGACGCTGGA
CATCGCGTCCAACAACCGTAAAGGCATCGCGTTTGCGGACTCGGGTGCGCACTGGCAATTGCATCGTCGTCTGGCTA
TGGCTACCTTCGCCCTGTTTAAGGATGGCGATCAGAAACTGGAGAAAATCATTTGCCAAGAGATTAGCACGCTGTGC
GACATGCTGGCAACCCATAATGGTCAATCTATTGACATTTCGTTCCCGGTCTTTGTGGCGGTCACCAATGTGATCAG
CCTGATTTGCTTTAACACGAGCTATAAGAATGGCGACCCGGAACTGAATGTGATCCAGAATTACAATGAGGGCATCA
TCGACAATTTGAGCAAGGACAGCCTGGTGGACTTGGTCCCGTGGCTGAAGATTTTCCCTAACAAAACGCTGGAAAAG
TTGAAAAGCCATGTCAAAATCCGCAACGATCTGCTGAACAAGATCCTGGAAAACTACAAAGAGAAGTTTCGTTCTGA
CAGCATTACTAACATGCTGGACACGCTGATGCAGGCCAAAATGAATTCCGATAACGGCAATGCAGGTCCGGATCAGG
ACAGCGAGCTGTTGAGCGATAACCATATCCTGACCACGATCGGTGACATCTTTGGTGCCGGTGTGGAAACCACCACC
AGCGTCGTCAAATGGACGCTGGCGTTCCTGCTGCACAATCCGCAGGTGAAAAAGAAGTTGTACGAAGAAATTGATCA
GAACGTTGGCTTCAGCCGCACCCCGACGATTTCCGACCGCAATCGTCTGCTGCTGTTGGAGGCAACGATTCGCGAAG
TTCTGCGCCTGCGTCCGGTTGCGCCAATGCTGATCCCGCACAAAGCCAATGTTGATTCTAGCATCGGTGAGTTCGCA
GTTGACAAAGGTACTGAAGTCATTATCAACTTGTGGGCCCTGCATCACAATGAGAAAGAGTGGCACCAGCCGGACCA
ATTCATGCCGGAACGTTTCCTGAACCCGGCAGGTACTCAACTGATCAGCCCGAGCGTGTCTTACCTGCCGTTCGGTG
CCGGTCCGCGCTCCTGTATTGGTGAGATCCTGGCGCGTCAGGAGCTGTTCCTGATTATGGCGTGGCTGCTGCAACGT
TTTGATCTGGAGGTGCCAGATGATGGCCAGCTGCCTTCCCTGGAAGGCATTCCGAAGGTTGTTTTCCTGATTGATAG
CTTTAAGGTCAAGATTAAGGTGCGCCAAGCGTGGCGCGAGGCACAAGCGGAAGGTAGCACCCACCACCATCACCACT
AA 		 	
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